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Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of multiple 
malignancies, including Kaposi’s sarcoma (KS) and primary effusion lymphoma (PEL). KSHV 
belongs to the gammaherpesvirus family, and it contains a large double-stranded DNA genome 
encoding a plethora of viral genes and non-coding RNAs. Understanding the interplay between 
the virus and the host is crucial for identifying therapeutical targets. KSHV viral interleukin-6 
(vIL-6) is a viral homolog of human IL-6. This viral protein is expressed in KSHV-associated 
malignancies and is known to deregulate signaling pathways. We found that vIL-6 induces the 
expression of integrin β3 (ITGB3), resulting in the surface expression of integrin αVβ3. We 
discovered that JAK/STAT signaling pathway is necessary for the induction of ITGB3. 
Moreover, we found that vIL-6 can induce the expression of ITGB3 in a paracrine manner which 
is physiologically relevant as vIL-6 can be detected circulating in patients suffering from KSHV-
associated malignancies. Importantly, depletion of ITGB3 hindered the ability of vIL-6 to 
promote angiogenesis. Therefore, we identified ITGB3 as a potential therapeutic target for 
KSHV-associated malignancies.  
The PI3K/Akt/mTOR pathway has been shown to contribute to cell survival and 
proliferation and is constitutively activated by some KSHV proteins. Unsurprisingly, the 
pathway is commonly deregulated in malignancies including non-Hodgkin lymphomas (NHL). 
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Given the importance of the pathway for cell survival, we reasoned that inhibiting the network 
with novel inhibitors should be a viable therapeutical approach. Miransertib and MK-4440 are 
small molecules that effectively inhibit Akt and have entered clinical development. Using in 
vitro and in vivo models of NHL, we explored targeting the Akt alone or in combination with the 
mTORC1 inhibitor, sirolimus. We found that the combination of miransertib and sirolimus 
synergistically reduced cell proliferation and tumor growth in NHL, including the KSHV-
associated PEL. These data suggest that targeting the PI3K/Akt/mTOR pathway with Akt 
inhibitors such as miransertib in combination with mTOR inhibitors serves as a broadly 
applicable therapeutic in NHL. In sum, with this dissertation, I undertook two different routes to 
better understand the importance of signaling pathways in KSHV-associated malignancies, with 
implications beyond viral cancers.  
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The worldwide prevalence of human cancers caused by infectious agents has been 
estimated to be approximately 15-20% (1). These infectious agents include the bacterium 
Helicobacter pylori, the parasite Opisthorchis viverrini and seven viruses. These human cancer-
causing viruses, or oncoviruses, include both DNA and RNA viruses. Since the discovery of the 
first human oncovirus, Epstein-Barr virus (EBV), in 1964, six additional viruses have been 
found to be etiologically related to several malignancies (2). The DNA oncoviruses are EBV, 
Kaposi’s sarcoma-associated herpesvirus (KSHV), human papillomaviruses (HPV), hepatitis B 
virus (HBV), and Merkel cell polyomavirus. The RNA oncoviruses are hepatitis C virus and 
human T-lymphotropic virus (HTLV) type 1. Although significant improvements have been 
made with regards to prevention, diagnosis, and treatment of viral cancers, as evidenced by the 
vaccines against HBV and HPV, the multi-step process by which viruses can induce cell 
transformation and consequently cancer is not entirely understood. As illustrated by Mesri and 
colleagues, viruses can hijack cellular processes to facilitate the dysregulated growth of cells, 
leading to tumor formation (2). Also, to modulate cell proliferation and prevent cell death, 
oncoviruses promote angiogenesis, providing the tumors with a continuous supply of nutrients. 
 
1A large part of this chapter previously appeared as an article in the journal Frontiers in Microbiology. The original 
citation is as follows: Rivera-Soto R & Damania B (2019) Modulation of Angiogenic Processes by the Human 
Gammaherpesviruses, Epstein-Barr Virus and Kaposi's Sarcoma-Associated Herpesvirus. Front Microbiol 10:1544. 
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Angiogenesis is one example of a deregulated process that facilitates the establishment 
of tumors. This is a multi-step process that leads to the formation and growth of new blood 
vessels from pre-existing vessels. The angiogenic process is essential for physiological 
processes such as embryonic development, tissue repair during wound-healing, and the female 
reproductive cycle (3). However, this process, which is tightly regulated by several pro- and 
anti-angiogenic factors, can be altered by cancer cells and result in enhanced tumorigenesis; the 
process itself is considered a hallmark of cancer (4). Angiogenesis occurs when the balance 
between pro- and anti-angiogenic factors is tilted towards the promotion of angiogenesis. This 
event is known as the “angiogenic switch,” which is an essential step during the progression and 
metastasis of a malignant tumor, as it can provide oxygen and nutrients required for tumor 
growth (5-7). The activation of the angiogenic switch can occur in both viral and non-viral 
cancers, but in the former, oncoviral factors are to some extent responsible for tilting the 
balance towards the induction of angiogenesis (Figure 1.1). 
The angiogenic process begins with the activation of endothelial cells. This process can 
be intercellularly initiated from the tumor cells by the transcription factors hypoxia-inducible 
factors (HIF) 1 and 2 (8). First, as a tumor grows, the tumor microenvironment becomes 
hypoxic, allowing the stabilization of HIF-1α. During normoxic conditions, prolyl-hydroxylases 
(PHDs) hydrolyze HIF-1α, which can then be recognized by the von Hippel-Lindau (VHL) 
tumor suppressor. This leads to the ubiquitin-mediated degradation of HIF-1α. However, in the 
absence of oxygen (or during oncogenic activation), PHDs cannot hydrolyze HIF-1α, which 
results in HIF-1α translocating to the nucleus and dimerizing with HIF-1β to activate the HIF-
responsive element (HRE)-containing promoters. Several pro- and anti-angiogenic factors, 
including vascular endothelial growth factor (VEGF), fibroblast growth factors (FGF), platelet-
3 
derived growth factor (PDGF), and several interleukins (IL) such as IL-6 and IL-8 are induced 
by HIF-1 (8).  
Following the induction of expression, these pro-angiogenic factors are secreted from 
the tumor cells and intercellularly bind and activate their respective receptors in endothelial 
cells (Figure 1.2). Activation of the receptors such as vascular endothelial growth factor 
receptor (VEGFR)-2, fibroblast growth factor receptor (FGFR), and Tie-2, stimulate the 
modulation of several signaling pathways, including phosphatidylinositol 3-kinase (PI3K)/Akt, 
mitogen-activated protein kinase (MAPK)/extracellular-regulated kinase (ERK), and Janus 
kinase (JAK)/signal transducer and activator of transcription (STAT) (9-11). This, in turn, 
further enhances angiogenesis by promoting cell survival, proliferation, and invasion (9).  
In addition to the tumor cells, the endothelial sprouting cells forming the new vessels 
induce the expression and activation of pro-migratory factors such as matrix metalloproteinase 
Figure 1.1 KSHV induces the angiogenic switch. 
KSHV activates pro-angiogenic factors and represses anti-angiogenic factors to activate the 
angiogenic switch promoting vessel formation and enhancing tumorigenesis. Created with 
Biorender. 
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enzymes (MMPs; described below). MMPs degrade extracellular matrix components (ECM) 
and facilitate cell movement. The expansion and cell movement allow for the branching of 
blood vessels. Notably, the secretion of pro-angiogenic factors by the tumor cells can also act as 
an attractant for the proliferating endothelial cells and recruitment of immune cells (12). 
Following the formation of the new blood vessel, pericytes are recruited and attached to newly 
matured endothelial cells (12). 
However, due to the fast and uncontrolled growth, and continuous stimulation associated 
with pathological angiogenesis, these tumorigenic blood vessels acquire an aberrant 
morphology that includes excessive branching with defective basement membrane and uneven 
pericyte coverage (13). These effects contribute to the tortuosity and leakiness of tumor-
associated blood vessels facilitating metastasis (13). Furthermore, the expansion of these new 
blood vessels allows for the formation of networks with existing vessels in a process known as 
anastomosis (14). Every tumorigenic process, including angiogenesis, requires the relay of 
signals through intricate networks of signal transduction cascades. Two commonly deregulated 
pathways that facilitate oncogenic processes are the JAK/STAT and PI3K/Akt/mTOR signaling 
pathways. 
JAK/STAT SIGNALING PATHWAYS 
The JAK/STAT signaling pathways are significant players in several cellular processes, 
including differentiation, proliferation, immune response, angiogenesis, and cell survival (15). 
The JAK family is composed of four members: JAK1, JAK2, JAK3, and TYK2. Activation of 
JAK occurs in response to the activation of certain transmembrane receptors, mainly cytokine 
receptors. JAKs are bound to the cytoplasmic domain of these receptors, and upon ligand-
binding, conformational changes allow the receptor/JAK dimers to bring the JAKs in close  
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proximity leading to their transphosphorylation (Figure 1.3) (16). Once JAKs are activated, they 
can phosphorylate the cytoplasmic tails of the receptor creating docking sites for the STAT 
family of proteins.  
The STAT family of proteins comprises seven members, STAT1, STAT2, STAT3, 
STAT4, STAT5a, STAT5b, and STAT6. After STATs are recruited to the receptor, JAKs 
Figure 1.2 Major cellular pathways converge to promote angiogenic processes.  
The cellular receptors PDGFR, VEGFR-2, and CXCR-1, are activated upon ligand-binding and 
mediates activation of major signaling pathways such as MAPK/ERK, PI3K/Akt, PLCγ/PKC, 
and JAK/STAT. The activation of these pathways results in the transcription of pro-angiogenic 
genes that can promote cell migration, invasion, and angiogenesis in autocrine and paracrine 
manners. Created with Biorender. 
6 
recognize and phosphorylate a conserved tyrosine residue (e.g., Y705 in STAT3). 
Phosphorylated STAT can form homo- or hetero-dimers with other STAT proteins in the 
family. The dimer is then translocated to the nucleus to bind target genes and promote their 
transcription (16, 17). These STAT-induced factors include proteins such as growth factors, 
interferon-regulated genes, and chemokines, that when expressed, can promote cell proliferation 
and survival. 
Dysfunction of the JAK/STAT pathway by either gain-of-function or loss-of-function 
mutations is frequent in certain cancers (18). Supraphysiological activation of JAK leads to 
constitutive activation of the signaling pathway causing detrimental effects on cells (16). 
Furthermore, somatic mutations in STAT3 are common in several hematological malignancies, 
such as in T-cell large granular lymphocyte leukemia, where up to 72% of patients carry a 
STAT3 mutation (19). Furthermore, mutations in JAK proteins lead to an alteration in the 
expression of programmed cell death-ligand (PDL) 1 in both the cancer cell and the tumor 
microenvironment, reducing the efficacy of treatments with checkpoint inhibitors (20, 21).  
The STAT3-driven tumorigenesis is believed to be the result of a combination of losing 
immune signaling while inducing pro-inflammatory responses in the tumor microenvironment 
(16). Several cytokines such as VEGF, IL-6, and IL-10 induce activation of STAT3, which 
results in the expression of even more cytokines leading to constant activation of tumor-
inducing factors (17). An example is the binding of IL-6 to the IL-6Rα and gp130, which leads 
to the activation of JAK/STAT3 signaling and drives multiple cellular processes associated with 
tumor progression by further inducing IL-6 and amplifying its signaling (22). 
7 
PI3K/AKT/MTOR SIGNALING PATHWAY 
The activation of phosphatidylinositol 3-kinase (PI3K) mediated by extracellular stimuli 
activating receptor tyrosine kinase (RTK) or G-protein coupled receptors (GPCR) results in the 
stimulation of this signaling pathway, which regulates multiple cellular processes such as 
protein translation, cell proliferation, and apoptosis (Figure 1.4) (23, 24). PI3K is composed of 
four different classes, with classes I and II being important for catalyzing the conversion of 
membrane-bound phosphatidylinositol (4,5)-bisphosphate (PIP2) into phosphatidylinositol 
Figure 1.3 Schematic of JAK/STAT signaling pathway. 
Stimulation of cytokine receptors results in the transphosphorylation and activation of JAK 
proteins. Activated JAKs can then phosphorylate the STAT family of proteins, which assemble 
as hetero- or homodimers and function as transcription factors driving the expression of a 
plethora of effectors with variable cellular functions. Created with Biorender. 
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(3,4,5)-trisphosphate (PIP3) (25). PIP3 is able to recruit pleckstrin homology (PH) domain-
containing proteins such as phosphoinositide-dependent kinase-1 (PDK-1) and protein kinase B 
(PKB; Akt). Phosphatase and tensin homolog (PTEN) is the negative regulator of the pathway. 
PTEN accomplishes this by dephosphorylating PIP3 back to PIP2 (23-25). Importantly, in some 
cancers, PTEN is commonly mutated and inactivated, allowing for the constitutive activation of 
the pathway (26).  
Akt is a significant kinase mediating the activation of the pathway. Three isoforms of 
Akt (Akt1, Akt2, Akt3) have been identified, and animal studies demonstrated that these 
proteins have some redundant and specific functions depending on the tissue (23). Of the three 
isoforms, Akt1 is the most widely expressed isoform, and throughout this dissertation, I will 
refer to this isoform when mentioning Akt. The initial activation of Akt occurs through the 
PDK-1-mediated phosphorylation of residue T308 (27). This phosphorylation occurs when both 
proteins are in close proximity due to PIP3-mediated re-localization of the proteins to the 
plasma membrane. Although Akt is active with only one phosphorylation mark (T308), 
complete activation is achieved when S473 also becomes phosphorylated (28). The 
phosphorylation of S473 is mediated by the mammalian target of rapamycin (mTOR) complex 
2 (mTORC2) (28). Other phosphorylation marks have also been studied and hypothesized to 
have a role in mediating cell localization and substrate specificity (23). Inactivation of Akt is 
mediated through the dephosphorylation of T308 by protein phosphatase 2A (PP2A) or K48-
linked ubiquitination mediated by various ubiquitin ligases, which triggers proteasomal-
dependent degradation (29, 30). 
Activation of Akt can have a plethora of effects ranging from cell proliferation and 
inhibition of apoptosis to protein translation and metabolism (23). Akt can modulate these 
9 
processes thanks in part to its multitude of substrates estimated to be in the hundreds. Typically, 
Akt phosphorylates Ser and Thr residues within the common motif R-X-R-X-X-S/T-ϕ (where X 
is any amino acid and ϕ is a large hydrophobic residue). In a substrate-dependent manner, the 
Akt-mediated phosphorylation can activate or inactivate its target (23). Amongst the most 
Figure 1.4 Schematic representation of the PI3K/Akt/mTOR signaling pathway.  
Stimulation of RTKs or GPCR results in the activation of PI3K, which converts PIP2 to PIP3. 
PIP3 facilitates Akt phosphorylation by PDK1 and mTORC2. Phosphorylated (active) Akt 
targets an arsenal of proteins resulting in the activation of cellular processes that promotes cell 
growth and survival. Created with Biorender. 
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studied Akt targets, we can find the forkhead box O (FOXO) family of transcription factors and 
the tuberous sclerosis complex (TSC) 2. 
Members of the FOXO family of transcription factors, which includes FOXO1, 3, 4, and 
6, are regulated by Akt phosphorylation (31, 32). Active Akt phosphorylates the proteins at 
different amino acids allowing for the recognition by the 14-3-3 family of proteins. Interaction 
with this family of proteins leads to the nuclear export of FOXO proteins inhibiting their 
function as transcription factors. Notably, several FOXO-regulated genes, such as Bim, p53 
upregulated modulator of apoptosis (PUMA), and tumor necrosis factor (TNF)-related 
apoptosis-inducing ligand (TRAIL), are apoptotic-inducer genes (33). Therefore, Akt-mediated 
inhibition of FOXO proteins is a component of Akt’s anti-apoptotic function. Besides apoptosis, 
the FOXO proteins mediate proliferative, cell growth, and metabolic signals (23). In summary, 
the FOXO family of proteins is an important Akt target that mediates many physiological 
processes. 
The major protein complex downstream of Akt is mTORC1. Activation of this complex 
is mediated through the Akt-induced inactivation of TSC2 (Figure 1.4) (34). TSC2 is a GTPase-
activating proteins (GAP) protein within the TSC, which also includes TSC1 and TBC1 domain 
family member 7. As a GAP protein, TSC2 promotes the conversion of Rheb-GTP to Rheb-
GDP. In its GTP-bound form, Rheb is an essential activator of mTORC1 (23, 34). Additionally, 
another GTPase family, Rags, facilitates the activation of mTORC1 by recruiting the complex 
to lysosomal surfaces where Rheb is located. This process occurs when sufficient levels of 
amino acids are present. Thus, upon Akt activation, the TSC-Rheb interaction is disrupted, 
allowing the release of Rheb, which can then interact and activate mTORC1 (34).  
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The mTOR protein is a Ser/Thr kinase that belongs to the PI3K-related kinase (PIKK) 
family (34). mTOR functions in two separate protein complexes, mTORC1 and mTORC2. 
mTORC1 is composed of mTOR, regulatory protein associated with mTOR (Raptor), 
mammalian lethal with Sec13 protein 8 (mLST8/GβL), proline-rich Akt substrate of 40 kDa 
(PRAS40), and DEP domain-containing mTOR interacting protein (DEPTOR). On the other 
hand, the mTORC2 complex is comprised of mTOR, mLST8, rapamycin-insensitive companion 
of mTOR (Rictor), DEPTOR, mSin1, and Protor1/2 (34). Interestingly, both complexes contain 
their own set of substrates driving a variety of different cellular processes.  
To promote protein synthesis, mTORC1 phosphorylates the p70-S6K protein, enabling 
the activation of eukaryotic initiation factor 4B (eIF4B), a component of the 5′ cap-binding 
eIF4F complex (35). Moreover, S6K is known to phosphorylate all the phosphorylatable 
residues of the ribosomal protein S6, a vital component of the ribosomes (36). Additionally, 
mTORC1 inhibits eukaryotic translation initiation factor 4E-binding protein (4EBP), which 
itself is an inhibitor of the eIF4F complex (37, 38). Thus, through two different and independent 
mechanisms, mTORC1 drives protein translation. In order to have enough building blocks for 
growing cells, mTORC1 targets substrates that promote a supply of nutrients such as lipids, 
nucleotides, and metabolites (34). On the other hand, the mTORC2 promotes cell survival and 
proliferation by targeting members of the large AGC family of protein kinases. Among these, 
Akt might be the most prominent member, which, as discussed above, can have a plethora of 
effects in promoting cellular processes.  
The PI3K/Akt/mTOR pathway is a complex network composed of proteins that are 
actively cross-talking with parallel signaling pathways such as JAK/STAT, Nuclear factor-
kappa B (NF-κB), and Ras/MAPK/ERK. Thus, indirect activation of the pathway can occur 
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through the overactivation of these additional pathways. Overactivation of these pathways can 
be mediated by genetic lesions, extrinsic factors such as viruses, or a combination of both. One 
such virus that takes advantage of the pathways is Kaposi’s sarcoma-associated herpesvirus 
(KSHV)(39).  
 
KAPOSI’S SARCOMA-ASSOCIATED HERPESVIRUS 
Kaposi’s sarcoma-associated herpesvirus (KSHV) is an enveloped double-stranded 
DNA virus that belongs to the γ-herpesvirus family. KSHV is associated with several human 
malignancies, including the endothelial cell-driven cancer Kaposi’s sarcoma (KS) and two B-
cell lymphoproliferative diseases: Multicentric Castleman’s disease (MCD) and primary 
effusion lymphoma (PEL). Although KS was first described almost 150 years ago, it was not 
until 1994 when genetic material resembling a herpesvirus was found in KS lesions but not in 
healthy tissue (40, 41). A short time after identifying KSHV as the etiologic agent of KS, the 
virus was also linked to PEL and MCD (42, 43). More recently, two other conditions have been 
described as related to KSHV infection. These are the KSHV inflammatory cytokine syndrome 
(KICS) and a specific type of osteosarcoma affecting the Uyghur ethnic population in Xinjiang, 
China (44, 45). Therefore, in less than three decades, a total of 5 conditions have been 
associated with KSHV, and it would not be surprising if more conditions are linked owing to 
the diverse cell tropism displayed by the virus, which includes epithelial, endothelial, 
fibroblasts, monocytes, macrophages, dendritic, and B-cells (46).  
Like other herpesviruses, KSHV infection is lifelong, and diseases primarily arise in the 
context of immunosuppression (47). Viral entry into the target cells is mediated through the 
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interaction of viral glycoproteins (e.g., gB, gpK8.1α, gH/gL, gM/gN) and cellular receptors 
(e.g., heparan sulfate, integrins, x-CT, Ephrin (Eph)A2, EphA4) (46, 48). Importantly, not all 
cells express the same receptors making the mechanism of viral binding and entry cell type-
dependent. The binding of KSHV to cellular receptors can activate intracellular signaling 
pathways to promote the internalization of the virion. Proteins such as integrins mediate the 
activation of signaling networks by interacting with kinases such as focal adhesion kinase 
(FAK) and Src (46). Following the engagement of these receptors and the subsequent activation 
of signaling networks, KSHV is internalized through processes such as endocytosis or 
micropinocytosis (46). 
Replication of KSHV takes place in the nucleus of the infected cells. Thus, following 
entry, virions need to be trafficked into this compartment through the cellular network of 
microtubules (49). This has been demonstrated as viral capsids colocalize with microtubules, 
and the chemical-induced destabilization of this cytoskeleton component disrupts transports 
without affecting binding nor entry (49, 50). Once internalized, capsids are transported by 
dynein motor proteins towards the nucleus, where they can establish their viral replication (50).  
Once in the nucleus, the viruses undergo an initial lytic replication cycle, where the 
whole viral genome of over 160 Kb is transcribed. This is then followed by establishing a latent 
life cycle, where only a handful of genes are expressed but sufficient to maintain viral 
replication (51). The latency locus includes the open reading frame (ORF) 71, ORF72, ORF73, 
ORF K12, and microRNAs (miRNAs). Induction of the lytic replication can be spontaneous and 
is controlled by the protein product of ORF50, known as replication and transcription activator 
(RTA) (47). Although KSHV-associated tumor cells are latently infected, a subset of them 
undergo lytic replication, which is hypothesized to contribute to viral tumorigenesis by 
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providing growth factors in a paracrine manner (2, 51). Many of these pro-tumorigenic factors 
are directly linked to the induction of tumorigenic processes and might provide for therapeutical 
targets (52, 53). Later in this chapter, I will discuss the mechanisms by which KSHV proteins 




Kaposi’s sarcoma (KS) was first described in the late 1800s by Hungarian dermatologist 
Moritz Kaposi (41). The two cases that he described were both in elderly European men 
showing multifocal pigmented skin lesions. This type of KS is what we now classify as classic 
KS, which usually occurs in elderly men of Mediterranean or Jewish ancestry and tends to 
present as an indolent disease (54). Furthermore, in the mid-1900s, KS cases were described in 
African children, which is now referred to as endemic KS. Endemic KS is prevalent in eastern 
and southern countries in Africa, and this type of KS tends to be aggressive in children affecting 
lymph nodes and visceral organs (54). However, it was not until the 1980s when KS cases arose 
dramatically during the AIDS epidemic (55). The early reports included severely 
immunocompromised young men who have sex with men that were suffering from a very 
aggressive form of KS, now classified as AIDS-related KS. Subsequently, in 1987, KS was 
recognized as an AIDS-defining clinical condition by the Centers for Disease Control (56). 
Another form of KS, known as iatrogenic KS, usually affects patients undergoing 
immunosuppressive treatment due to organ transplants (57, 58). Importantly, recent reports are 
showing that as people living with suppressed HIV age, they are 35-60 times more likely to 
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develop KS than the general population (59). Although KSHV is the causative agent of all 
forms, the diseases can have different courses ranging from indolent to fulminant.  
The seroprevalence of KSHV is geographically dependent. In some regions of sub-
Saharan Africa, more than 90% of people carry the virus, whereas, in some places of the 
Mediterranean basin, the prevalence is about 25%. On the other hand, in northern Europe, Asia, 
and North America, less than 10% of the population is infected (54). Not surprisingly, cases of 
KS are much more common in areas with higher viral seroprevalence.  
Kaposi’s sarcoma tumors are composed of spindle-shaped cells. These cells have an 
elongated cytoplasm and nuclei and express endothelial cell markers (60, 61). Interestingly, 
KSHV can induce a transcriptional reprogramming from blood to lymphatic cells and vice versa 
(62). The KS tumors are highly angiogenic, resulting in dark patches, usually in the lower 
extremities but can involve lymph nodes and internal organs at later stages. KS is generally 
treated with chemotherapeutic agents such as liposomal anthracyclines and paclitaxel. The Food 
and Drug Administration (FDA) recently cleared the immunomodulatory compound 
pomalidomide for patients with or without recurrent HIV infection (63). Although KS can be a 
detrimental condition affecting patients physically and emotionally, prompt diagnosis and 
intervention can significantly improve the quality of life.  
PRIMARY EFFUSION LYMPHOMA 
Similar to KS, clinical cases of PEL were described before discovering its etiologic 
agent in the mid-1990s (42, 64). PEL is classified as an aggressive post-germinal center B-cell 
non-Hodgkin lymphoma, characterized by lymphomatous effusions in body cavities such as the 
peritoneal, pleural, and pericardium (65). Cells contain a large cytoplasm with features similar 
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to plasmablastic cells. Furthermore, PEL is a monoclonal disease that expresses B-cell 
activation (CD45, CD30, CD38, CD7) and plasma (CD138, Mum-1) cell markers while lacking 
markers of mature B-cells (CD20). Unlike other non-Hodgkin lymphomas (NHL), PEL cells do 
not usually display genetic lesions altering the expression of common lymphoma-related genes 
such as Myc, B-cell lymphoma (BCL) 6, or p53, making KSHV the primary driver of 
transformation (66). Approximately 50-100 copies of the KSHV genome can be found in PEL 
cells, and they are usually co-infected with the other human γ-2 herpesvirus, EBV (67, 68). 
Similar to KS, the disease primarily develops in the context of immunosuppression with a 
median survival of 6-10 months (69, 70).  
Given the aggressiveness of the disease, therapeutic intervention is necessary, and in 
some instances, it depends on the patient’s HIV status. Usually, the current treatment involves 
regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) or the 
more aggressive alternative, EPOCH (CHOP plus etoposide). In contrast to other NHL, PEL 
cells do not usually express the target of rituximab, CD20 (65). However, it has been 
hypothesized that treatment with anti-CD20 might still be helpful by limiting the growth of cells 
producing inflammatory cytokines, which are essential for PEL growth in the microenvironment 
(71). Nevertheless, developing new therapeutics is critical to improving these patients' quality of 
life and life expectancy. 
MULTICENTRIC CASTLEMAN’S DISEASE 
In the mid-1950s, Doctor Benjamin Castleman described cases of angiofollicular lymph 
node hyperplasia localized to the mediastinum (72-74). This form of Castleman’s disease is 
what we now recognize as the hyaline form. Another variant, which is usually composed of 
plasmablastic and plasmacytic cells and involving multiple areas of the body (multicentric), is 
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recognized as multicentric Castleman’s disease (MCD), which is associated with KSHV (43, 
75). MCD presents as a lymphadenopathy and is a highly inflammatory disease with patients 
displaying high levels of interleukins such as IL-6 and IL-10 (76-78). If left untreated, MCD 
can have a lethal course with a median survival of 2 years and can develop concurrently with 
KS and PEL (79-83). Interestingly, in contrast to PEL and KS, MCD frequently develops in 
HIV-suppressed or HIV-negative patients (72).  
MCD cases develop as part of a hyperproliferation of λ-restricted plasmablasts in the 
outer mantle zone or marginal zones of the lymph nodes expressing high levels of IL-6 (76, 83). 
Expression of CD20 is variable, but treatment with the anti-CD20 molecule, rituximab, is 
recommended (84-86). The importance of IL-6 in the pathogenesis of MCD is demonstrated by 
the approval of siltuximab, an anti-IL-6 antibody, for the treatment of KSHV-negative MCD. 
Notably, IL-6 signaling is mimicked by the KSHV viral homolog, viral IL-6, usually expressed 
at low levels during the latent life cycle but highly overexpressed during lytic replication (87-
90). Unlike KS, MCD patients display increased KSHV viral loads due to more lytic 
replication, resulting in increased vIL-6 expression (91-94). As discussed below, vIL-6 activates 
JAK/STAT signaling, which leads to overexpression of IL-6 and other pro-tumorigenic factors 
such as VEGF (87). Thus, it appears that both human and virally-encoded IL-6 coordinates to 
create a pro-inflammatory environment that drives MCD.  
KAPOSI SARCOMA INFLAMMATORY CYTOKINE SYNDROME AND KAPOSI 
SARCOMA-IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME 
Kaposi sarcoma inflammatory cytokine syndrome (KICS) was first described in 2010 
from 6 patients showing symptoms of MCD and co-infected with HIV and KSHV but lacked 
the pathological features associated with MCD (44). Like MCD, KICS patients have elevated 
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levels of vIL-6, IL-6, IL-10, and KSHV viral loads suggesting an active viral lytic replication 
(44, 95, 96). Another inflammatory condition associated with KSHV is KS-immune 
reconstitution inflammatory syndrome (KS-IRIS). Given the concurrent infection of KSHV and 
HIV, patients are usually treated with combination antiretroviral therapy (cART) to suppress 
HIV replication. This treatment promotes the reconstitution of the immune system, which 
decreases the frequency of opportunistic infections and AIDS-associated diseases. However, in 
25-35% of patients, the restoration of the immune system can lead to a deregulation of the 
immune response, causing a deterioration of a known disease or the “unmasking” of previous 
asymptomatic pathogens (97-100). IRIS is believed to result from the rapid expansion of TNF-α 
and inteferon (IFN)-γ-secreting lymphocytes, which might reactivate KSHV and exacerbate KS 
(101, 102). The combination of cART with chemotherapy agents is effective at repressing the 
progression of KS (101).  
 
ROLES OF KSHV IN DEREGULATING SIGNALING PATHWAYS 
Initial studies in KS and PEL illustrated the importance of tumor cells in inducing 
tumorigenic processes such as angiogenesis by, in part, promoting VEGF and VEGFR (103-
107). Interestingly, factors such as VEGF can enhance the infectivity of the virus, and its 
expression is increased as early as 30 minutes post-infection, suggesting a role in mediating 
infection (108). Following infection, KSHV triggers the reactivation of silenced genes such as 
paired box protein 2 (PAX-2). Generally restricted to embryogenesis, KSHV-mediated 
induction of PAX-2 leads to the expression of C-C motif chemokine ligand 2 (CCL-2) and Akt, 
which contributes to the angiogenic and invasiveness potential of endothelial cells, two 
important processes in tumorigenesis (109). Furthermore, KSHV-infected endothelial cells have 
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increased PI3K/Akt activity, which, as mentioned above, is a significant contributor to viral-
induced tubule formation (110). Additionally, KSHV-infected endothelial cells express and 
secrete many other pro-angiogenic factors. Some of these proteins include HIF-1α, HIF-2α, IL-
8, growth-regulated alpha (GRO-α), CCL-2, and angiopoietin-2 (Table 1.1) (109, 111-115).  
The demand for oxygen and nutrients during tumorigenic processes such as 
angiogenesis triggers reactive oxygen species (ROS), contributing to the pathological process 
(116). Consequently, KSHV tumor cells rely on ROS production, as treatment with antioxidants 
represses pro-angiogenic factors and decreases the formation of KS-like tumors in mice (117, 
118). For example, in an NF-κB-dependent but HIF-1α-independent manner, ROS and hypoxic 
conditions induce the expression of galectin-1, driving angiogenic phenotypes in KS-like 
tumors (119). Moreover, the redox functions of apurinic/apyrimidinic endonuclease (APE) 1, 
which can affect several transcription factors, are involved in KSHV-induced angiogenesis 
(120). Thus, ROS production by KSHV-infected endothelial cells is needed to form KS-like 
tumors and their vasculature. 
KSHV infection of endothelial cells promotes the expression of integrin subunits β1 and 
β3 (121, 122). In endothelial cells, integrins (e.g., αVβ1 and αVβ3) play a role in KSHV entry 
by binding to glycoprotein B (49). Activation of integrins such as αVβ3 induces 
phosphorylation of FAK and tyrosine kinase Src, promoting the release of stored angiogenin-2 
(Ang-2) (123). Ang-2 plays an essential role in the vasculature of KSHV tumors by serving as a 
ligand for the tyrosine kinase receptor, Tie-2 (124). Activation of Tie-2 enhances VEGF 
signaling and induces activation of PI3K/Akt and MAPK/ERK pathways (125). Thus, in 
endothelial cells, integrins facilitate viral binding and entry, and they are also involved in cell 
migration and angiogenesis.  
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Table 1.1 Major pro- and anti-angiogenic factors modulated by KSHV viral factors. 
 
Furthermore, KSHV infection of endothelial cells promotes cell migration through the 
induction of MMP-1, MMP-2, and MMP-9 (145). This process is facilitated in part by the 
KSHV-induced activation of the AP-1 transcription factor. The disruption of cell-cell junctions 
Major Pro-angiogenic Factor Viral Factor Cell Type Reference 
Angiogenin LANA Endothelial (126) vGPCR 
Angiopoietin-2 vIL-6 Lymphatic Endothelial (127) vGPCR 
ANGPTL-4 vGPCR Endothelial (128, 129) 
COX-2 vFLIP Endothelial (130) 
CCL-2/MCP-1 vIL-6 Endothelial (131) 
CCL-3/MIP-1α vGPCR Epithelial (132) CCL-4/MIP-1β 
CXCL-1/Gro-α vGPCR Epithelial (132) 
CXCL-8/IL-8 vGPCR Epithelial (132) K15 Epithelial (133) 
CXCL-12/SDF-1 vGPCR Epithelial (132) 
EGFL-7 LANA Endothelial (134) 
FGF-2/FGFR vIL-6 Fibroblast (135) 
HIF 
LANA Various (136) 
vIRF3 Endothelial (137) 
vGPCR Fibroblast (138) 
IL-6 
vGPCR Epithelial (132) 
K15 Epithelial (133) 
vIL-6 Various (139) 
MMP-1 K15 Epithelial (133) 
MMP-2 vGPCR Endothelial (140) 
MMP-9 K1 Endothelial (141) 
PDGF/PDGFR vGPCR Endothelial (142) 
VEGF 
  
vGPCR Fibroblast (138) 
K1 Endothelial / Epithelial (141) 
K15 Epithelial (133) 
vIL-6 Fibroblasts  (87) 
vIRF3 Endothelial (137) 
miRNA Endothelial (143) 
Major Anti-angiogenic Factor Viral Factor Cell Type Reference 
THBS-1 miRNAs Epithelial and B-cells (144) 
TIMP-2 vGPCR Endothelial (140) 
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enables cell migration, and in endothelial cells promotes vascular permeability. KSHV induces 
this process by modulating the expression or phosphorylation of vascular endothelial (VE)-
cadherin (146-148). Notably, the viral proteins K1, K5, and viral (v)GPCR are significant 
contributors to these processes during both latent and lytic phases (148-150).  
In just a couple of decades, researchers have identified several viral factors, expressed 
during both latent and lytic cycles, that are involved in modulating tumorigenic processes such 
as angiogenesis and may represent viable targets against KSHV-associated malignancies. Next, 
I will review the current knowledge of how individual genes contribute to the activation of 
signaling pathways.  
LATENCY-ASSOCIATED NUCLEAR ANTIGEN 
The latency-associated nuclear antigen (LANA), encoded by ORF73 and homologous to 
EBV’s Epstein-Barr nuclear antigen 1, is an important latent protein that tethers the KSHV 
episome to the host genome, allowing viral replication during regular cellular division (151). 
LANA utilizes several mechanisms to promote tumorigenesis, including inhibiting tumor 
suppressors and miRNAs to promote activation of transcription factors that modulate pro-
tumorigenic proteins.  
The LANA-mediated inhibition of the VHL and p53 tumor suppressors promotes the 
stabilization of HIF-1α (Figure 1.5) (136, 152). LANA also stabilizes the Notch effector Hey-1, 
preventing its degradation and facilitating Notch signaling (153). Furthermore, LANA 
sequesters death-associated protein 6, allowing Ets-1 to modulate the expression of the pro-
angiogenic factors VEGFR-1, VEGFR-2, and epidermal growth factor-like domain 7 (134, 
154). Another mechanism by which LANA enhances the expression of the transcription factors 
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Ets-1 and Ets-2 involves the repression of cellular miRNAs miR-221 and miR-222 (155). 
Inhibition of these miRNA leads to an increase in Ets-1 and Ets-2, resulting in the expression of 
pro-angiogenic genes. 
Moreover, LANA increases the expression and secretion of Ang-2 and the extracellular 
matrix metalloproteinase inducer (EMMPRIN; also known as CD147), promoting invasiveness 
by activating signaling pathways such as PI3K/Akt and MAPK/ERK (126, 156, 157). In KSHV-
infected endothelial cells, EMMPRIN induces the pro-angiogenic metalloproteinases 
ADAMTS-1 (a disintegrin and metalloproteinase with thrombospondin motifs), ADAMTS-9, 
and heme-oxygenase 1 (158, 159). To conclude, LANA plays at least two essential roles in 
KSHV-infected cells: ensuring the maintenance of latency and promoting pro-tumorigenic 
processes. 
vFLIP AND vCYCLIN 
ORF71 and ORF72 are expressed together as they are located in a bicistronic mRNA 
and code for the viral FLICE (FADD-like interferon converting enzyme)-like inhibitory protein 
(vFLIP) and the cyclin D homolog, vCyclin, respectively (160). Both genes are expressed 
during latency, and their proteins modulate pro-survival and cell proliferation pathways. The 
introduction of vFLIP in endothelial cells modulates the expression of several genes that are 
essential for blood vessel development (161). Notably, vFLIP can directly interact with IκB 
kinase (IKK) α, IKKβ, and IKKγ/NF-κB essential modulator (NEMO) complexes, promoting 
IκBα destruction and thus NF-κB activation (162, 163). Additionally, vFLIP uses an alternative 
pathway to induce the activation of NF-κB by promoting the degradation of the histone 
deacetylase complex components Sin3A-associated protein 18 and histone deacetylase (HDAC) 
1, which target p65 for deacetylation (164). Importantly, activation of NF-κB is essential for 
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vFLIP-induced endothelial cell migration, invasion, and angiogenesis (164). In an NF-κB-
dependent manner, and in coordination with LANA, vFLIP increases expression of the 
epigenetic modifier enhancer of zeste homolog 2, which in turn modulates the pro-angiogenic 
factor EphB2 (165). 
Furthermore, in endothelial cells, vFLIP plays an essential role in KSHV-induced 
expression and secretion of prostaglandin-endoperoxide synthase 2 (PTGS2/COX-2) and 
prostaglandin E2 (166-168). This induction of COX-2 not only requires NF-κB but is also 
dependent on PI3K/Akt and p38/MAPK (130). Finally, both vFLIP and vCyclin can induce 
expression of the host microRNA cluster miR-17/92, which targets Smad-2 and perturbs 
transforming growth factor-beta (TGF-β) signaling (169). This process is hypothesized to 
modulate viral-induced angiogenesis as, paradoxically, TGF-β has both pro- and anti-
angiogenic functions (170). Although not much is known about the role of vCyclin in 
angiogenesis, these studies have demonstrated that, mostly through the activation of NF-κB, 
vFLIP is important for KSHV-induced angiogenesis.  
KAPOSINS 
The ORF K14 encodes kaposin A, while kaposins B and C transcription begins upstream 
of ORF K14. Kaposins A and C have not been thoroughly studied, although it has been shown 
that kaposin A has oncogenic potential as it can induce focus formation in Rat-3 and NIH3T3 
cells and form tumors in nude mice (171, 172). Additionally, the expression of kaposin B results 
in the activation of pro-inflammatory and pro-angiogenic signaling involving p38/MK-2 and 
STAT3 (Figure 1.5) (173, 174). Importantly, activation of p38/ Mitogen-activated protein 
kinase-activated protein kinase 2 (MK-2) promotes the accumulation of AU-rich element-
containing mRNAs, including prospero homeobox protein 1 (PROX-1; (175)). Consequently, 
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this process allows for the stabilization of PROX-1 mRNA, contributing to KSHV-induced 
lymphatic reprogramming of blood endothelial cells (176). Another mechanism by which 
kaposin B modulates angiogenesis involves the inactivation of the host miRNAs miR-221 and 
miR-222 in a c-Myc-dependent manner (177). As mentioned above, these two miRNAs target 
the transcription factors Ets-1 and Ets-2. To conclude, these studies highlight the roles of the 
kaposins in mediating viral-induced pathogenesis and possibly contributing to tumor 
angiogenesis. 
KSHV MICRORNAS 
KSHV encodes 12 precursor microRNAs that are processed into at least 25 mature 
miRNAs that target viral and host mRNAs to maintain latency while also promoting 
tumorigenesis (178-180). These miRNAs are expressed during latency and are abundant in 
KSHV-associated malignancies (181-183). In order to promote angiogenesis, several miRNAs 
target cellular anti-angiogenic and anti-proliferative proteins such as thrombospondin 1 (THBS-
1) (144, 184). KS tumor tissues show low levels of THBS-1, and several miRNAs have been 
identified to target its transcript, resulting in a reduction in TGF-β activity (144, 185).  
Moreover, the KSHV miRNA K12-6-5p targets the breakpoint cluster region, enhancing 
Rac-1 activity and promoting tubule formation (186). Rac-1 belongs to the Rho family of 
GTPases involved in angiogenesis and reorganization of the cytoskeleton. Additionally, miRNA 
K12-6-5p targets the metastasis suppressor CD82, allowing c-Met to be activated, and induces 
endothelial cell invasion and angiogenesis (187). In addition to the viral proteins known to 
activate the PI3K/Akt pathway (39), KSHV miR-K12-3 targets G protein-coupled receptor 
kinase 2, promoting the activation of IL-8R/Akt (188). This increase in Akt activity enhances 
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the invasiveness and angiogenic potential of endothelial cells (188). Furthermore, KSHV 
miRNAs modulate the activation of the JAK/STAT signaling pathway. For example, expression 
Figure 1.5 Several KSHV proteins and miRNAs promote angiogenesis by activating 
cellular signaling pathways. 
The viral genes LANA, vFLIP, kaposin B, vIRF-3, and the miRNAs miR-K12 induce 
activation of major transcription factors such as HIF-1α, NF-κB, AP-1, and STAT-3. 
Additionally, the viral proteins K1, K15, vGPCR, vIL-6, and vPK cooperate in the activation of 
multiple signaling pathways promoting expression of angiogenic factors resulting in stronger 
viral-induced tumorigenesis. Created with Biorender. 
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of miR-K12-6-3p promotes the degradation of SH3 domain-binding glutamic acid-rich protein, 
relieving STAT3 repression and allowing nuclear translocation and expression of pro-
angiogenic genes such as MMP-13, VEGF-A, and VEGFR-2 (Figure 1.5) (143). Together, these 
studies illustrate the mechanisms that a handful of viral miRNAs utilize to promote 
tumorigenesis.  
K1 
The ORF K1 is located on the extreme left end of the KSHV genome (189). It is an 
immunoreceptor tyrosine-based activation motif (ITAM)-containing transmembrane 
glycoprotein with transforming capacities, able to immortalize endothelial cells (190, 191). 
Through its ITAM, K1 recruits SH2-containing proteins such as Syk and phosphoinositide 
phospholipase C (PLC) γ-1 and induces their constitutive activation (Figure 1.5) (192, 193). 
Expression of K1 in endothelial cells leads to an increase in activation of the PI3K/Akt 
pathway, resulting in VEGF secretion and consequently angiogenic activity (141, 194). 
Additionally, K1 can synergize with the HIV protein Nef to induce the expression of cellular 
miR-718, which targets PTEN and promotes the activation of the PI3K/Akt pathway (195). 
Similarly, through the modulation of another cellular miRNA, miR-891a-5p, K1 synergizes 
with HIV-1 Tat to promote angiogenic processes by activating NF-κB signaling (196). Thus, K1 
activation of several signaling pathways, chiefly PI3K/Akt, promotes the angiogenic activity of 
endothelial cells.  
K15 
Located at the right end of the viral genome, ORF K15 encodes a transmembrane 
protein composed of eight alternatively spliced exons (197). K15 modulates pro-angiogenic 
cytokines and chemokines such as IL-6, IL-8, and CCL-20 (133, 198). The cytoplasmic tail of 
27 
K15 contains SH2- and SH3-binding motifs that recruit and constitutively activate PLCγ-1 
(199). Moreover, K15 activates signaling pathways involving Ras, c-Jun N-terminal kinases 
(JNK), NF-κB, and the transcription factors AP-1 and nuclear factor of activated T-cells 
(NFAT) (Figure 1.5) (200, 201). Recruitment of PLCγ-1 and activation of NFAT are essential 
for K15 to induce pro-angiogenic phenotypes such as endothelial cell tubule formation (198, 
202). This angiogenic process involves the expression of regulator of calcineurin 1, which is 
induced explicitly by K15 via activation of calcineurin (198). In sum, several studies have 
suggested that most of the pro-angiogenic signaling induced by K15 is mediated through the 
activation of NFAT.  
VIRAL INTERLEUKIN-6 
The ORF K2 encodes vIL-6, and its expression can be detected at low levels during 
latency but increases upon lytic replication. As the name indicates, vIL-6 is the viral homolog of 
human IL-6, and they share some properties, such as the ability to induce activation of the 
JAK/STAT signaling pathway (Figure 1.5) (89, 203-206). However, in contrast to IL-6, which 
requires both components of the IL-6 receptor (IL-6R; gp80 and gp130), vIL-6 can induce 
signaling through gp130 in the absence of IL-6Rα (gp80). This allows the viral protein to 
constitutively activate the pathway promoting cell proliferation, migration, and angiogenesis 
(87, 131, 206-208). The involvement of vIL-6 in mediating angiogenesis was demonstrated 
when vIL-6-expressing NIH3T3 cells formed highly vascularized tumors in nude mice (87). 
vIL-6 is an essential player in the pathogenesis of KSHV-associated MCD, as the viral cytokine 
can be detected in the serum of patients, induce MCD-like disease in mice, and promote the 
secretion of IL-6, a significant contributor to the disease (92, 139, 209).  
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vIL-6 is sufficient, but not necessary, for KSHV-induced differentiation of blood to 
lymphatic endothelial cells (210). Notably, the induction of the lymphatic markers PROX-1, 
VEGFR-3, and podoplanin (PDPN), expressed in KS tumor cells, requires the activation of both 
JAK/STAT and PI3K/Akt pathways (210). Moreover, in addition to the KSHV proteins 
mentioned above, vIL-6 also represses TGF-β2 signaling to levels seen with KSHV infection 
(211). The suppression of TGF-β2 is essential for viral-induced tubule formation (211). Similar 
to K1, vIL-6 has been found to synergize with HIV-1 proteins Tat and Nef to promote 
angiogenesis by activating the PI3K/Akt pathway (135, 212). vIL-6 is also involved in 
promoting endothelial cell migration, and possible angiogenesis, by activating proteins such as 
carcinoembryonic antigen-related adhesion molecule 1, hypoxia-upregulated protein 1, DNA 
methyltransferase 1, and CCL-2 (131, 207, 208). In conclusion, a multitude of studies using 
both in vitro and in vivo models have demonstrated the highly pro-angiogenic functions of vIL-
6 and how this viral protein might contribute to KSHV-associated malignancies.  
VIRAL G-PROTEIN COUPLED RECEPTOR 
ORF74 encodes the early lytic protein vGPCR, the viral homolog to cellular CXCR-1 
(213, 214). Activation of the IL-8 receptor CXCR-1 is widely known to be pro-angiogenic in 
endothelial cells (Figure 1.2) (215). vGPCR activates major signaling pathways including p38, 
JNK, PI3K/Akt, MEK/ERK, JAK/STAT, and Wnt/β-cat, and the transcription factors AP-1, 
cyclic adenosine monophosphate-response element-binding protein, NFAT, and NF-κB (Figure 
1.5) (138, 216-220). Activation of these signaling pathways leads to the vGPCR-mediated 
secretion of pro-angiogenic factors such as IL-6, IL-8, GRO-α, CCL-3, CCL-4, stromal cell-
derived factor 1 (SDF-1β), and VEGF (132). In contrast to VEGF, whose expression is mainly 
dependent on HIF-1α, secretion of the other cytokines is dependent on the GTPase Rac-1 (132, 
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138, 221). Additionally, the Hippo pathway has recently been highlighted as an essential 
contributor to angiogenesis (222, 223). vGPCR activates the downstream mediators of the 
Hippo pathway, Yes-associated proteins/Tafazzin, which in turn may facilitate the angiogenic 
process by mediating VEGFR signaling and expression of angiopoietin-2 (224, 225). 
vGPCR immortalizes HUVECs and induces the expression of VEGFR-2, which is vital 
for the survival of these cells (226, 227). Furthermore, vGPCR transforms NIH3T3 cells and 
promotes the formation of highly vascularized tumors in nude mice (216). Secreted factors from 
vGPCR-expressing cells, especially VEGF, induce tubule formation in endothelial cells, 
suggesting the involvement of paracrine signaling in promoting angiogenesis (226). Finally, 
conditioned media from vGPCR-expressing cells induce the expression in HUVECs of pyruvate 
kinase 2, which acts as a coactivator of HIF-1 to promote aerobic glycolysis and tubule 
formation (228).  
As a potent inducer of angiogenic processes, vGPCR modulates the expression of other 
pro-angiogenic proteins such as Ang-2 and angiopoietin-like (ANGPTL) 4. Ang-2 is necessary 
for the survival of KSHV-infected endothelial cells, and ANGPTL4 promotes angiogenesis and 
vascular permeability (126, 128, 129). Additionally, in coordination with vIL-6 and dependent 
on MAPK/ERK signaling, vGPCR induces the expression of angiopoietin-2 in lymphatic 
endothelial cells (127). Furthermore, through activation of Src, vGPCR induces membrane type 
(MT) 1-MMPs and represses tissue inhibitor of metalloproteinases (TIMP)-2, resulting in an 
increase of MMP-2 and arterial endothelial-cell tubule formation (140). Taken together, these 
studies demonstrate that vGPCR is a potent inducer of pro-angiogenic processes, and thus, it is 
expected to contribute significantly to KSHV-associated malignancies.  
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VIRAL INTERFERON REGULATORY FACTORS 
KSHV encodes four viral homologs to cellular interferon regulatory factors (IRFs) 
(229). They play an essential role in inhibiting their cellular counterparts’ innate function. 
Although it is likely that all four vIRFs contribute to the pathogenesis of KSHV, especially by 
modulating Notch and TGF-β/Smad signaling, only vIRF-3 has been identified to have a role in 
promoting angiogenesis (229). vIRF-3, also known as LANA-2, is a latently expressed protein 
that interacts with HIF-1α, promoting its stabilization and pro-angiogenic signaling, including 
VEGF expression (Figure 1.5) (137, 230). Furthermore, vIRF-3 can also interact with HDAC-5, 
sequestering it in the nucleus, and inducing expression of the lymphatic markers PDPN and 
PROX-1 (231). These markers, which are also detected in KSHV-infected endothelial cells, 
contribute to the spindle-shape form characteristic of KS (231). Finally, vIRF-3 is necessary for 
KSHV-induced lymphatic endothelial cell tubule formation and sprouting (231). Thus, in 
addition, to playing a role in repressing host antiviral response, vIRFs may contribute to KSHV-
induced angiogenesis.   
VIRAL CC CHEMOKINE LIGANDS 
KSHV encodes three CC chemokine ligands (CCLs), vCCL-1 (ORF K6), vCCL-2 (ORF 
K4), and vCCL-3 (ORF K4.1) (203). These were previously known as viral macrophage 
inhibitory proteins. These viral proteins can interact with cellular CC-chemokine receptors and 
inhibit their signaling. All three vCCLs have been found to induce pro-angiogenic phenotypes 
in both in vitro and in vivo models (232-234). In particular, vCCL2 has been identified as 
capable of binding to multiple chemokine receptors, thus able to act on several cell types (235). 
Therefore, vCCLs may play an important role in the tumor microenvironment by recruiting 
immune cells.  
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VIRAL PROTEIN KINASE 
The viral protein kinase (vPK) encoded by ORF36 is one of two kinases expressed by 
KSHV (236). The other kinase is the homolog of cellular thymidine kinase encoded by ORF21. 
The expression of vPK is detected mainly during lytic replication, although it can also be 
detected in the absence of full lytic replication. This expression during latency is hypothesized 
to occur during hypoxic conditions as HIF proteins upregulate vPK expression via HIF response 
elements located at the promoter of the ORF34-37 cluster (237). Notably, vPK activates the 
JNK pathway by phosphorylating mitogen-activated protein kinase kinase (MKK)-4 and MKK-
7 (Figure 1.5) (238). 
Furthermore, vPK mimics the activity of the cellular protein S6K1, promoting protein 
synthesis by activating ribosomal protein S6 and eIF4B (239). As mentioned above, both S6 and 
eIF4B are downstream components of the PI3K/Akt pathway that promote translation of HIF-
1α, enhancing angiogenesis (240). Significantly, the expression of vPK augments anchorage-
independent growth and promotes endothelial cell tubule formation (239). In addition to its 
oncogenicity in vitro, vPK expressed in transgenic mice generates a hyperproliferation of B-
cells and a higher incidence of B-cell non-Hodgkin’s lymphomas (241). Together, these studies 




 Cancers are the result of an accumulation of failures to control the growth of an aberrant 
cell. This multistep and multifactorial process is highly controlled by an intricate system of 
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players that communicates internally (within the cells) and externally (with adjacent cells). 
Oncoviruses such as KSHV hijack these signaling networks manipulating the infected cell and 
their neighbors to prolong its “survival” and replication. Consequently, constitutive activation 
of pro-survival signals can cause transformation resulting in cancers. Elucidating the 
mechanisms by which KSHV manipulates these signaling pathways is vital for the development 
of targeted therapies. To accomplish this goal, this dissertation focused on two main objectives: 
1) to uncover pro-tumorigenic cellular proteins deregulated by the KSHV protein vIL-6, and 2) 
to test the therapeutical efficacy of inhibiting the PI3K/Akt/mTOR signaling pathway against 
viral and non-viral NHL. In the following chapter, I will discuss the first objective, and in 
Chapter 3, I will present the results obtained for my second objective. I will conclude with 
Chapter 4, where I will discuss the future directions towards understanding KSHV-associated 
malignancies, which can be applicable to other cancers. 
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CHAPTER 2: KAPOSI’S SARCOMA-ASSOCIATED HERPESVIRUS VIRAL 




Integrins are heterodimeric membrane glycoproteins that consist of an alpha (α) and beta 
(β) subunit. These cell surface proteins are receptors for extracellular matrix (ECM) proteins, 
growth factors, cytokines, immunoglobulins, and matrix-degrading proteases (242). One of the 
beta subunits, β3, can dimerize with αIIb in platelets and αV in other cell types, including 
endothelial cells. Integrin αVβ3 binds to adhesive proteins such as von Willebrand factor, 
fibrinogen, and fibronectin. The binding of these ligands can induce the “outside-inside” 
signaling through the integrin, resulting in endothelial cell migration (243), angiogenesis (243, 
244), and TGF-β1 signaling (245, 246). Integrin αVβ3 expression and function are of 
significant interest as its expression is upregulated in several forms of cancer and correlates with 
progression of malignancies (242, 247). 
A receptor for cellular proteins, integrin αVβ3 has also been reported to be a receptor 
for viruses, including Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human 
herpesvirus-8 (HHV-8) (248-250). KSHV, a double-stranded DNA virus from the γ-herpesvirus 
family (251), was first isolated from a Kaposi’s sarcoma (KS) patient and found to be the 
 
2This chapter previously appeared as an article in the journal Journal of Virology. The original citation is as 
follows: Rivera-Soto R, Dissinger NJ, & Damania B (2020) Kaposi’s Sarcoma-Associated Herpesvirus Viral 
Interleukin-6 Signaling Upregulates Integrin β3 Levels and Is Dependent on STAT3. Journal of Virology 
94(5):e01384-01319. 
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causative agent of this cancer (40). Subsequently, it was demonstrated that KSHV also causes 
the B-cell malignancy, primary effusion lymphoma (PEL) (42). KSHV is also associated with 
the proliferative disorder multicentric Castleman’s disease (MCD) (43). DiMaio and colleagues 
reported that latent infection of KSHV increases integrin β3 (ITGB3) expression in endothelial 
cells (122). This increase causes the infected cells to bind more strongly to select ECM 
components. Additionally, knockdown of ITGB3 results in a decreased ability of infected cells 
to form tubules in an in vitro model of angiogenesis. These data suggest that KSHV upregulates 
ITGB3, which can play a role in the angiogenic processes of KSHV-infected endothelial cells 
(122). However, the mechanism by which the virus mediates the induction of ITGB3 has not 
been characterized.  
KSHV encodes over 80 open reading frames (ORFs), which consist of latent and lytic 
genes. Most infected cells contain a latent virus, expressing only a small subset of genes that 
encode proteins and non-coding RNAs. Upon reactivation, the virus starts expressing lytic 
genes in an ordered fashion and produces new viral progeny (252). ORF K2 encodes for viral 
interleukin-6 (vIL-6), a homolog of human IL-6 (hIL-6) (203-205). During latency, vIL-6 
expression is detected at low levels but significantly increases during lytic replication (253). 
Similar to hIL-6, secreted vIL-6 binds to the IL-6 receptor (IL-6R, composed of gp80 and 
gp130 subunits) and induces the JAK/STAT signaling cascade (89, 203). However, while the 
cell readily secretes hIL-6, vIL-6 is mainly localized to the endoplasmic reticulum (ER). Here, 
vIL-6 interacts with gp130, a component of the IL-6R, and induces JAK/STAT signaling in an 
intracellular manner (206). Through activation of transcription factor STAT3, vIL-6 induces 
cell proliferation (203, 208, 254) as well as migration (131, 207, 208). vIL-6 also induces 
angiogenesis and hematopoiesis, aiding in the growth of tumors (87, 255). 
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We report that vIL-6 expressed from different cell types is capable of inducing ITGB3 at 
the mRNA and protein levels. Phosphorylation of STAT3 is required for this induction, as 
indicated by assays using drug inhibitors and siRNA knockdowns. Interestingly, in endothelial 
cells, vIL-6 is a stronger inducer of ITGB3 when compared to the human homolog, even though 
both are capable of inducing STAT3 signaling. Finally, we show how this phenotype may 
promote KSHV pathogenesis by contributing to angiogenesis. These studies highlight vIL-6 as 
a player in KSHV-induced ITGB3.  
 
MATERIALS AND METHODS 
CELL CULTURE 
All endothelial cell-based assays used human telomerase reverse transcriptase (hTERT)-
immortalized human umbilical vein endothelial cells (HUVEC) cultured in Endothelial Basal 
Medium 2 (Lonza) or Endothelial Cell Growth Medium 2 (PromoCell) and their respective 
supplement kits as described previously (141). BJAB and TREx-Rta-BCBL-1 cells were 
maintained in RPMI 1640 medium (Corning). The cell line iSLK.219 (harboring latent 
rKSHV.219) was maintained in Dulbecco's Modified Eagle Medium (Corning) in the presence 
of 1 μg/ml of puromycin (Corning), 250 μg/ml of G418 (Sigma), 400 μg/ml of hygromycin 
(Corning). All media were supplemented with 10% heat-inactivated FBS, 1% 
penicillin/streptomycin, and 1% L-glutamine. The iSLK.219 and TREx-Rta-BCBL-1 cells were 
reactivated by supplementing the media with 1 µg/ml of doxycycline for up to 24 h.  
36 
PRODUCTION OF LENTIVIRUS VECTORS AND STABLE CELL LINES  
Production of the empty vector (EV) and vIL-6 lentivirus and the construction of stable 
cell lines were described previously (Appendix 1) (207). The hIL-6 lentiviral vector was cloned 
similarly. Briefly, hIL-6 was inserted into a lentivirus vector with puromycin resistance. 
Lentivirus was produced using ViraPower lentiviral expression system (Invitrogen), and cells 
were transduced by spin inoculation in the presence of polybrene (8 µg/mL). BJABs expressing 
EV, vIL-6, or hIL-6 were made using the same lentivirus and spin inoculation procedure. 
RNA ISOLATION AND REAL-TIME QPCR  
RNA was isolated from cells using the RNeasy Plus Mini Kit (Qiagen). cDNA was 
obtained from 1 µg total RNA using the iScript cDNA Synthesis kit (Bio-Rad). At least three 
biological replicates were performed for each condition used in experiments, with three 
technical replicates for each sample. Real-time (RT) qPCR was performed on a Quantstudio 6 
Flex RT PCR machine (ThermoFisher) using SensiFAST SYBR Lo-Rox real-time PCR master 
mix (Bioline). PCR primer sequences used for ITGB3 were reported previously (256). To 
amplify actin cDNA, the forward primer 5’-TCATGAAGTGTGACGTGGACATC-3’ and 
reverse primer 5’-CAGGAGGAGCAATGATCTTGATCT-3’ were used.  
IMMUNOBLOTTING  
Cells were collected, and lysates were prepared from washed pellets using NP-40 lysis 
buffer (0.1% NP-40, 150 mM NaCl, 50 mM Tris HCl pH 8.0, 30 mM β-glycerophosphate, 50 
mM NaF, 1 mM Na3VO4, 1 Roche protease inhibitor tablet per 50 mL). Samples were clarified 
by centrifugation at 16,000 x g for 10-15 minutes, and protein concentration was determined by 
Bradford assay (Bio-Rad). Lysates were resolved on SDS-PAGE gels. ITGB3 (4702S), ITGAV 
(4711S), gp130 (3732S), pSTAT3 Y705 (9131S), total STAT3 (4904S), and secondary HRP-
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conjugated antibodies (anti-rabbit (7074) and anti-mouse (7076)) were purchased from Cell 
Signaling Technology (CST). Human IL-6 antibodies were obtained from Origene (TA300413) 
and CST (12153S). The vIL-6 antibody was purified from the supernatant of v6m 12.1.1 
hybridomas (ATCC) (88) using magnetic Protein A/G beads (ThermoFisher). Actin (sc-47778) 
antibody conjugated with HRP was purchased from Santa Cruz Biotechnology. 
CO-IMMUNOPRECIPITATION  
Cell lysates containing equal amount of proteins from emtpy vector (EV) of vIL-6 
(FLAG-tagged) HUVEC were pre-cleared with EZview™ Red Protein A Affinity Gel (P6486; 
Sigma) and mouse non-specific IgG (sc-2025; Santa Cruz Biotechnology). Supernatants were 
collected and incubated with 40 µl of EZview™ Red ANTI-FLAG® M2 Affinity Gel (F2426; 
Sigma) overnight at 4°C. Beads were pelleted and washed twice with lysis buffer and twice with 
cold Tris-buffered saline. Bound proteins were eluted with 3x FLAG peptide (F4799; Sigma). 
All immunoprecipitation inputs and eluted proteins were resolved in SDS-PAGE gels, and 
immunoblottings were performed as above.  
LUCIFERASE REPORTER ASSAY  
Two hundred thousand HEK293T cells were plated per well into a 24-well plate. 
Twenty-four hours post-seeding, cells were co-transfected with 500 ng/well of a vIL-6-
expressing plasmid or the corresponding empty vector (EV) backbone (a gift from Britt 
Glausinger) (257), and 150 ng/well of the ITGB3-luciferase reporter plasmid (HPRM23183-
PG04) purchased from GeneCopoeia. Transfection was performed with Lipofectamine 3000 
(ThermoFisher) according to the manufacturers' protocol. Supernatants were collected 48 h 
post-transfection. The Gaussia luciferase and the internal control, secreted embryonic alkaline 
phosphatase (SEAP), were measured using the Secrete-Pair™ Dual Luminescence Assay Kit 
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(GeneCopoeia) according to the manufacturers' protocol. To confirm vIL-6 expression, protein 
lysates were prepared, and immunoblots performed as described.  
FLOW CYTOMETRY  
Endothelial cells were plated after trypsinization and incubated for 48 h. Cells were then 
collected using Versene and counted. Five hundred thousand cells per sample were washed and 
resuspended in 80 µL of FACS buffer (PBS + 2% FBS + 2 mM EDTA) along with 20 µL 
human FcR Blocking Reagent (MACS Miltenyi Biotec), then allowed to incubate for 10 
minutes at 4°C. Cells were then spun down and stained with 2 µg αVβ3 antibodies (MAB1976; 
MilliporeSigma) in 100 µL FACS buffer and incubated on ice in the dark for 30 minutes. After 
primary staining, cells were washed three times, then stained for 30 minutes on ice in the dark 
with 300 ng goat α-mouse antibody conjugated with Alexa Fluor (AF) 488 fluorophore 
(ThermoFisher). After washing off the excess secondary stain, cells were fixed in FACS buffer 
containing 1% formaldehyde. Samples were run on a MACSQuant VYB flow cytometer 
(Miltenyi Biotec). The analysis was conducted using FlowJo software. 
CONDITIONED MEDIUM PREPARATION AND TREATMENT  
HUVEC and BJAB stable cell lines were incubated for 24 h in serum- or supplement-
free medium. The TREx-Rta-BCBL-1 and iSLK.219 cells were reactivated for 24 h in complete 
medium. The conditioned medium was then collected, centrifuged, filtered, and then added to 
naïve HUVEC cells supplemented with completed medium. Lysates were harvested 24 h post-
treatment. 
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NEUTRALIZATION ANTIBODY ASSAY 
Conditioned medium from stable HUVEC were created as stated above except for 
certain wells that received 10 µg mouse non-specific IgG (Santa Cruz Biotechnology) or 10 µg 
purified vIL-6 antibody. Conditioned medium was then added to immortalized HUVEC and re-
supplemented with the antibody. After a 24-hour incubation, lysates were collected, and 
immunoblots performed. 
siRNA TRANSFECTIONS AND DRUG INHIBITOR TREATMENT 
siRNAs were transfected into cells using Lipofectamine RNAiMax reagent 
(ThermoFisher) and allowed to incubate for up to 72 h before lysate collection or cell use in 
other assays. ON-TARGETplus SMARTpool siRNAs for human ITGB3 (L004124), IL-
6ST/gp130 (L005166), as well as the non-targeting control (D001810) siRNAs, were purchased 
from Dharmacon. Silencer Select siRNA targeting STAT3 (4390824), as well as the respective 
negative control, were obtained from ThermoFisher. For STAT3 drug inhibition, cells were 
treated with 20 µM of cryptotanshinone (MedChemExpress) or vehicle (DMSO). Cells were 
incubated for 48 h post-treatment before lysates were collected. 
CELLTITER-GLO VIABILITY ASSAY 
One hundred thousand cells were seeded into a 96-well white plate (Greiner Bio-One). 
siRNAs were transfected as above, and cells incubated for up to 48 h. CellTiter-Glo (Promega) 
was used to determine cell viability according to the manufacturer's protocol. Luminescence 
was measured in a CLARIOstar plate reader (BMG Labtech).  
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RECOMBINANT HUMAN IL-6 AND sIL-6RΑ TREATMENT  
For hIL-6 treatment, HUVEC were plated on six-well plates with complete medium. 
Twenty-four hours after plating, the medium was replaced with fresh medium containing rhIL-6 
(Peprotech) at the indicated concentrations. After incubating cells for 48 h with rhIL-6, lysates 
were prepared, and immunoblots performed as described above. For the experiment with sIL-
6Rα, cells were treated for 24 h similarly to above, but in the presence or absence of sIL-6Rα 
(GenScript).  
ADHESION ASSAY 
Cells were plated in 100 mm dishes and transfected the next day with siRNAs as stated 
above. Cells were removed from the plate using Versene and washed in PBS twice. Cells were 
resuspended in 500 µL serum-free medium at a concentration of 106 cells/mL. Two and a half 
microliters of the fluorescent dye calcein-AM, obtained from Invitrogen Vybrant Cell Adhesion 
Kit (ThermoFisher), were added to the cell suspension and incubated for 30 minutes at 37°C. 
During the incubation, 8-well strips that contained either fibronectin or vitronectin (Millicoat 
Cell Adhesion strips; Millipore) were allowed to warm up to room temperature and washed in 
PBS. After the 30-minute incubation, cells were washed in prewarmed medium three times, 
then diluted to 105 cells/mL and 100 µL added to each well. The cells were allowed to adhere to 
the ECM components for 30 minutes at 37°C. Nonadherent cells were removed by gentle 
washing (repeated five times) in a warmed medium. After the final wash, 200 µL PBS was 
added to each well, and the fluorescence was measured on a CLARIOstar plate reader (BMG 
Labtech). 
41 
TUBULE FORMATION ASSAY 
Empty vector- or vIL-6-HUVEC were plated and transfected with siRNAs as indicated 
above. Forty-eight h post-transfection, cells were detached from the plates, counted, and 1.25 x 
105 cells in a total of 1 ml complete medium were seeded on top of 300 µl Matrigel (Corning) in 
the wells of a 24-well plate. At least four images were taken per each well between 3- and 4-h 
post-seeding, and the number of branching points was manually calculated using ImageJ.  
STATISTICS 
Statistical tests (Student’s t-test for RT-qPCR, Mann-Whitney test for luciferase assay, 
and Kruskal-Wallis for adhesion and tubule formation assays) were calculated using GraphPad.  
 
RESULTS 
VIRAL IL-6-EXPRESSING CELLS HAVE INCREASED LEVELS OF ITGB3.  
Our lab has previously reported microarray data that indicated human umbilical vein 
endothelial cells (HUVEC) stably expressing vIL-6 had increased levels of ITGB3 mRNA 
compared to cells expressing the empty vector (EV) (131). High levels of ITGB3 expression in 
vIL-6-expressing HUVEC were confirmed with RT-qPCR (Figure 2.1A). We next performed 
immunoblots probing for ITGB3 and found that the protein level was also increased in the vIL-
6-HUVEC (Figure 2.1B). Additionally, we wanted to know whether the higher levels of ITGB3 
mRNA and protein were due to increased ITGB3 transcription. HEK293T cells were co-
transfected with a vIL-6-expressing plasmid or the corresponding EV control and a luciferase 
reporter plasmid. Expression of vIL-6, as detected by immunoblotting, led to a significant 
increase in the expression of luciferase (Figure 2.1C). The results suggest that vIL-6 promotes 
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the activation of the ITGB3 promoter and consequently increases the ITGB3 mRNA and protein 
levels.   
It has been suggested that the surface expression of the heterodimer αVβ3 is determined 
by the expression of ITGB3 as integrin αV (ITGAV) is usually excessively expressed in cells 
(258). To assess the levels of ITGAV, we performed immunoblots with cell lysates from EV- 
and vIL-6-HUVEC. As expected, vIL-6-HUVEC showed a slight increase in the protein levels 
of ITGAV (Figure 2.1D). Furthermore, to determine if the increase in total ITGB3 resulted in 
Figure 2.1 HUVEC stably expressing vIL-6 have increased ITGB3 mRNA and protein 
levels. 
(A) Relative ITGB3 mRNA expression in stable HUVEC normalized to the expression levels 
in EV cells. (B) Integrin β3 protein expression in the total cell lysate of stable HUVEC. (C) 
Top: Relative luciferase expression from a luciferase reporter under the control of an ITGB3-
promoter transfected into HEK293T cells. Bottom: Immunoblots for vIL-6 and actin of 
transfected HEK293T cells. (D) Integrin αV protein expression in the total cell lysate of stable 
HUVEC. (E) Surface expression of integrin αVβ3 in stable HUVEC was measured using flow 
cytometry. The gray histogram represents EV HUVEC, and the white histogram represents 
vIL-6 HUVEC. **P < 0.01; ***P < 0.001 
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increased surface expression, we performed flow cytometry analysis using an αVβ3 antibody. 
Histograms comparing the geometric means of fluorescence intensity indicate that vIL-6-
HUVEC have a two-fold increase in levels of surface αVβ3 integrin (Figure 2.1E). Together, 
these results suggest that the expression of vIL-6 in HUVEC promotes an increase in the 
expression of ITGB3, leading to higher surface expression of integrin αVβ3.  
VIRAL IL-6-EXPRESSING CELLS CAN INDUCE ITGB3 EXPRESSION IN A 
PARACRINE MANNER.  
We next wanted to determine whether vIL-6-expressing endothelial cells induce ITGB3 
through paracrine signaling. To explore this possibility, we collected conditioned medium (CM) 
from both the EV- and vIL-6-HUVEC and added them to naïve HUVEC at a 1:1 ratio with fully 
supplemented medium. After 24 h, we were able to detect an increase in ITGB3 mRNA (Figure 
2.2A) and protein (Figure 2.2B) from the HUVEC that were treated with the vIL-6-containing 
conditioned medium.  
In addition to endothelial cells, B-cells are another cell type that is readily infected in 
vivo (259-262). In KS lesions, the cells that express the highest quantities of vIL-6 are from 
invading lymphocytes (263). For these reasons, we constitutively expressed EV or vIL-6 in 
BJABs, a B-cell line. Conditioned medium from these vIL-6-expressing BJAB cells induced 
ITGB3 mRNA and protein expression in HUVEC similarly to what we observed from the 
HUVEC-conditioned medium (Figure 2.2C and D).  
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To determine whether secreted vIL-6 was necessary for the induction of ITGB3 or if it 
was another secreted factor from stable vIL-6 cells, we performed a neutralization assay (Figure 
(A and B) HUVEC were treated with conditioned medium from EV- or vIL-6-expressing 
HUVEC for 24 h, followed by the comparison of ITGB3 (A) mRNA levels and (B) protein 
levels. (C and D) Similar experiments were conducted using conditioned medium from EV- 
and vIL-6-expressing BJABs. (E) Conditioned medium were collected from EV- and vIL-6-
HUVEC in the presence of non-specific mouse IgG or mouse anti-vIL-6 IgG. This conditioned 
medium was then placed on HUVEC. After 24 h, lysates were collected, and immunoblots 
performed for actin and ITGB3. CM = conditioned medium; NS = non-specific. *P < 0.05; **P 
< 0.01. 
Figure 2.2 vIL-6 induces ITGB3 expression in a paracrine manner. 
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2.2E). Conditioned medium were created containing no antibody, mouse non-specific IgG, or 
mouse α-vIL-6 IgG. These conditioned medium were then placed on naïve HUVEC, further 
supplemented with antibody, and incubated for 24 h. As expected, cells treated with the EV-
conditioned medium, regardless of the antibody supplement, did not induce ITGB3. On the 
other hand, cells that were treated with the mock or non-specific antibody containing vIL-6-
HUVEC-conditioned medium had increased levels of ITGB3. However, cells that were treated 
with the vIL-6-HUVEC-conditioned medium that contained the vIL-6 specific antibody had 
ITGB3 levels similar to the EV-conditioned-medium-treated cells. These results demonstrate 
that secreted vIL-6 is involved in the induction of ITGB3.  
LYTIC REPLICATION PROMOTES THE EXPRESSION OF ITGB3 IN A 
PARACRINE MANNER.  
Since vIL-6 expression in latently-infected cells is relatively low (253), we wanted to 
determine whether induction of the lytic life cycle would promote the expression of ITGB3. To 
test this, we reactivated a KSHV-infected cell line, iSLK.219, for 24 h and harvested protein 
lysates. Although the induction of lytic replication significantly increased the expression of vIL-
6, the levels of ITGB3 remained relatively similar to un-reactivated cells (Figure 2.3A). These 
results suggest that the contribution of vIL-6 to ITGB3 expression in infected cells may take 
place mostly during latency.  
Given that vIL-6 expression in iSLK.219 cells was significantly increased during the 
induction of the lytic life cycle (Figure 2.3A), we asked whether these levels of vIL-6 were 
comparable to the vIL-6-expressing HUVEC. We found that the expression of vIL-6 in the 
reactivated iSLK.219 was slightly higher than in the stable vIL-6-HUVEC (Figure 2.3B). The 
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minimal change in the expression of ITGB3 following lytic reactivation, despite vIL-6 
expression, might be due to the difference in cell type as iSLK.219 are considered epithelial 
cells.  
The results from Figure 2.2 showed that secreted vIL-6 induces the expression of ITGB3 
in a paracrine manner. Since reactivated iSLK.219 cells express high levels of vIL-6, we 
investigated if secreted factors such as vIL-6 can induce the expression of ITGB3 in naïve 
HUVEC. To address this question, we reactivated iSLK.219 and collected the conditioned 
Figure 2.3 vIL-6 from lytically replicating cells promotes the expression of ITGB3 in a 
paracrine manner.  
(A) iSLK.219 were reactivated with doxycycline for 24 h, and the levels of ITGB3, vIL-6, and 
actin were detected by immunoblotting. (B) Lysates from reactivated (24 h post-doxycycline) 
iSLK.219 and vIL-6-expressing HUVEC were resolved in SDS-PAGE, and vIL-6 expression 
was detected by immunoblotting. (C) HUVEC were treated for 24 h with conditioned medium 
from latent or reactivated iSLK.219 (24 h post-doxycycline). Immunoblots were performed 
with HUVEC lysates and iSLK.219 conditioned medium. (D) Conditioned medium were 
collected from TREx-Rta-BCBL-1 after 24 h DMSO (Latent) or doxycycline (Reactivated) 
treatment. Conditioned medium was supplemented with non-specific mouse IgG or mouse anti-
vIL-6 IgG and placed on HUVEC. After 24 h, lysates were collected, and immunoblots were 
performed in addition to the BCBL-1 conditioned medium. React. = reactivated cells; CM = 
conditioned medium; NS = non-specific. 
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medium 24 h post-doxycycline treatment. The conditioned medium from the un-reactivated and 
reactivated iSLK.219 cells was mixed with HUVEC medium and added to naïve HUVEC for 24 
h. Importantly, vIL-6 was detected in the cell-free conditioned medium collected from 
reactivated cells but not from the DMSO-treated cells. Similar to the results obtained from the 
conditioned medium of vIL-6-expressing-HUVEC (Figure 2.2A and B), cells cultured in the 
conditioned medium from reactivated cells showed a higher expression of ITGB3 than cells 
cultured in the conditioned medium from un-reactivated cells (Figure 2.3C).  
We also investigated whether vIL-6 secreted from primary effusion lymphoma cells was 
able to induce ITGB3 in a paracrine manner. Therefore, we reactivated TREx-Rta-BCBL-1 cells 
for 24 h and collected conditioned medium. Filtered conditioned medium from reactivated cells 
contained vIL-6 and was able to promote the expression of ITGB3 in HUVEC (Figure 2.3D). 
Importantly, vIL-6 antibodies blocked the induction of ITGB3 driven by the conditioned 
medium from reactivated BCBL-1 cells. Together, these results suggest that although lytically 
replicating cells do not induce the expression of ITGB3, secreted vIL-6 from iSLK.219 and 
BCBL-1 cells can induce ITGB3 in neighboring uninfected endothelial cells.  
STAT3 SIGNALING IS NECESSARY FOR vIL-6-MEDIATED ITGB3 INDUCTION.  
A previous report examining the effect of high αVβ3 integrin levels in breast cancer 
cells found that STAT3 contributes to the invasiveness of these cells (264). This finding 
indicated to us a possible link between STAT3 and αVβ3 activity. Since it is well established 
that vIL-6 interacts with gp130 to induce JAK2/STAT3 signaling (89, 265), we wanted to 
examine the relationship between this signaling pathway and ITGB3 in vIL-6-expressing cells. 
To determine whether vIL-6 interacts with gp130 in HUVEC, we performed co-
immunoprecipitations with FLAG-antibody-conjugated beads to immunoprecipitate FLAG-
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tagged vIL-6 (207). The proteins bound to vIL-6 were eluted with a FLAG peptide and resolved 
on an SDS-PAGE gel. The results showed that gp130 co-immunoprecipitated with vIL-6 in 
HUVEC (Figure 2.4A). Furthermore, to assess the importance of the pathway in inducing 
ITGB3, we knocked-down gp130 in EV- and vIL-6-HUVEC and performed immunoblots. The 
depletion of gp130 reduced vIL-6-mediated induction of phosphorylated STAT3 and ITGB3, 
suggesting that activation of STAT3 may be essential in this process (Figure 2.4B). 
To further test whether STAT3 is necessary for this process, we treated EV- and vIL-6-
HUVEC with the STAT3 inhibitor, cryptotanshinone. After 48 h, we observed the expected 
decrease in STAT3 phosphorylation as well as a decrease in total ITGB3 expression (Figure 
2.4C). This result indicates that vIL-6-induced STAT3 signaling is essential for ITGB3 
induction. To confirm this data, we transfected cells with a STAT3-specific siRNA and 
observed the same loss of ITGB3 levels in the vIL-6-HUVEC (Figure 2.4D). We then 
performed a similar experiment in which naïve HUVEC were first transfected with the STAT3 
siRNA, followed by treatment with EV- or vIL-6-conditioned medium. We observed that 
knockdown of STAT3 attenuated ITGB3 induction by the vIL-6-containing conditioned 
medium (Figure 2.4E). Together, these results suggest that activation of STAT3 is necessary for 
the ability of vIL-6 to induce ITGB3 in endothelial cells.  
HUMAN IL-6 IS NOT A STRONG INDUCER OF ITGB3 AS IS vIL-6 IN HUVEC. 
Since vIL-6 and hIL-6 can both activate STAT3, we hypothesized that hIL-6 could 
induce ITGB3, as well. To test this hypothesis, we collected lysates from HUVEC expressing 
EV, vIL-6, or hIL-6 and performed immunoblotting (Figure 2.5A). Surprisingly, hIL-6 did not 
affect levels of ITGB3. To confirm these results, stable HUVEC were supplemented for 48 h  
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Figure 2.4 JAK/STAT3 signaling is necessary for vIL-6-induced ITGB3.  
(A) Whole-cell lysates from EV- and vIL-6-HUVEC were immunoprecipitated with a FLAG 
(vIL-6) antibody. The eluates and inputs were resolved by SDS-PAGE and immunoblots were 
performed for the indicated proteins. (B) EV- and vIL-6-HUVEC were transfected with 
siRNAs for 72 h, and lysates were probed for the indicated proteins. (C) EV- and vIL-6-
HUVEC were treated with the STAT3 inhibitor cryptotanshinone (0 or 20 µM) for 48 h. 
Lysates were then collected and immunoblots performed for the indicated proteins. (D) EV- 
and vIL-6-HUVEC were transfected with siRNAs for 48 h, and lysates were probed for the 
same proteins as in panel C. (E) HUVEC were transfected with siRNAs against a non-targeting 
control or STAT3. Twenty-four hours post-transfection, cells were treated with conditioned 
medium from EV- or vIL-6-HUVEC and incubated for an additional 24 h before lysates were 
collected and used for immunoblots. NTC = non-targeting control; CM = conditioned medium; 
H = HUVEC 
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with recombinant (r) hIL-6. These results indicate that even in the presence of rhIL-6, levels of 
ITGB3 only increase in vIL-6-expressing cells. We next prepared conditioned medium from 
HUVEC and BJABs that contained EV, vIL-6, or hIL-6. These conditioned medium were then 
used to treat naïve HUVEC for 24 h, after which the lysates were collected (Figure 2.5B). 
Again, we observed a substantial increase in ITGB3 protein levels in cells treated with the vIL-
Figure 2.5 Human IL-6 is not a strong inducer of ITGB3 as is vIL-6 in HUVEC.  
(A) Immunoblots of total cell lysates from HUVEC expressing EV, vIL-6, or hIL-6 treated for 
48 h in the presence of recombinant hIL-6 at the indicated concentrations. (B) Immunoblots of 
HUVEC treated with conditioned medium from EV-, vIL-6-, and hIL-6-expressing HUVEC 
and BJABs. (C) Similar to (A), but EV- and vIL-6-HUVEC were grown for 24 h in the 
presence of rhIL-6 (250 ng/ml), soluble IL-6Rα, (250ng/ml) or both. rhIL-6 = recombinant 
hIL-6; CM = conditioned medium; sIL-6R = soluble IL-6Rα. 
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6-conditioned medium. Cells that were treated with the EV- or hIL-6-conditioned medium had 
no increase or a very modest increase in ITGB3 protein compared to EV control cells. These 
results suggest hIL-6 is not a potent inducer of ITGB3 as compared to vIL-6 in HUVEC.  
The induction of signaling pathways by hIL-6 can occur through two different but 
similar mechanisms known as classical- and trans-signaling (266, 267). In classical-signaling, 
hIL-6 binds to membrane-bound IL-6Rα (gp80), which interacts with gp130, leading to the 
intracellular activation of the JAK/STAT signaling pathway. This process is restricted to cells 
that express the membrane-bound receptor, which includes hepatocytes, some leukocytes, and 
some epithelial cells (266). In contrast, the trans-signaling pathway occurs when secreted hIL-6 
binds to the soluble form of the IL-6Rα. This hIL-6/soluble (s) IL-6R complex binds gp130 and 
induces activation of the JAK/STAT signaling pathway. Importantly, since gp130 is 
ubiquitously expressed, this process can take place even in cells that lack expression of the 
membrane-bound IL-6Rα. 
Recently, it was shown that HUVEC could support both mechanisms, but activation of 
the trans-signaling pathway by treating cells with both recombinant hIL-6 and sIL-6R led to 
higher and longer activation of STAT3 (268). For this reason, we hypothesized that 
supplementing cells for 24 h with both hIL-6 and sIL-6Rα will result in high levels of activated 
STAT3 and, thus ITGB3. Immunoblots show that EV-HUVEC treated with both recombinant 
proteins displayed an increase in phosphorylated STAT3, confirming the activation of the 
pathway (Figure 2.5C). Importantly, this activation also increased ITGB3 levels similar to those 
seen in the vIL-6-expressing cells (Figure 2.5C). However, the addition of the recombinant 
proteins did not enhance vIL-6-mediated induction of ITGB3. Altogether, the data suggest that 
in endothelial cells, activation of IL-6R plays a crucial role in the induction of ITGB3, and in 
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comparison, to its cellular homolog, vIL-6 can accomplish this even in the absence of soluble 
IL-6Rα.  
INTEGRIN β3 EXPRESSION INCREASES vIL-6-HUVEC ADHESION.  
DiMaio et al. demonstrated that KSHV-infected endothelial cells adhere more readily to 
the ECM proteins, fibronectin, and vitronectin (122). This increase in adhesion could be 
inhibited by the addition of Arginine-Glycine-Aspartic acid (RGD) peptides, which interfere 
with several integrin-ECM interactions. We wanted to examine if the increased amount of 
ITGB3 in vIL-6-HUVEC resulted in increased adherence to fibronectin and vitronectin. EV- 
and vIL-6-HUVEC were transfected with non-targeting control (NTC) or an ITGB3-targeting 
pool of siRNAs (Figure 2.6A). Knockdown of ITGB3 did not affect cell viability (Appendix 2). 
Cells were stained with a fluorescent dye and then allowed to adhere to wells coated with 
fibronectin or vitronectin (Figure 2.6B and C, respectively). We found that vIL-6-HUVEC 
transfected with NTC siRNAs had increased adherence to fibronectin-coated wells, but had 
relatively the same adherence to vitronectin as compared to EV-HUVEC. However, when 
Figure 2.6 ITGB3 aids in vIL-6-HUVEC adhesion to ECMs.  
(A) EV- and vIL-6-HUVEC were transfected for 48 h with non-targeting control or ITGB3 
siRNAs, and cell lysates were collected for immunoblots to confirm knockdown efficiency. (B) 
Cells treated as in panel A were stained with calcein-AM and plated for 30 minutes on wells 
pre-coated with fibronectin. Unattached cells were removed by gentle washes, and 
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ITGB3 was knocked down in vIL-6-HUVEC, the fluorescent signal, indicating the number of 
attached cells, significantly decreased for both ECM components, whereas the signal for EV-
HUVEC did not show a significant decrease. These results indicate that vIL-6 expression makes 
cell attachment to the ECM components, fibronectin, and vitronectin, more heavily dependent 
on ITGB3. 
VIRAL IL-6-INDUCED TUBULE FORMATION IS MEDIATED THROUGH ITGB3.  
vIL-6 has been previously reported to aid in angiogenesis (87, 212, 255, 269). Since KS 
is highly vascularized, we sought to determine if this was the case for vIL-6-expressing cells, as 
well. EV- and vIL-6-HUVEC were treated with NTC or ITGB3 siRNAs for 48 h. Cells were 
then placed on top of Matrigel and incubated for up to four hours. The number of branching 
points was manually calculated from at least thirty-two images. The results showed that vIL-6-
HUVEC transfected with NTC siRNA had significantly more branch points than EV-HUVEC 
(Figure 2.7A and B). The number of branching points, however, significantly decreased when 
ITGB3 was knocked down in vIL-6-HUVEC; this decrease was not observed in EV-HUVEC 
depleted for ITGB3. These results indicate that ITGB3 is involved in vIL-6-mediated 




The heterodimer αVβ3 is hypothesized to be important in several cancers and viral 
infections. A role for integrin αVβ3 has been suggested in KSHV pathogenesis, specifically in 
viral infection (248-250) and angiogenesis (122). Though KSHV infection has been 
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demonstrated to induce ITGB3 (122), and the viral protein gB is shown to interact with integrin 
αVβ3 (249), no specific KSHV protein has been identified as responsible for ITGB3 induction. 
In this report, we demonstrate that ITGB3 is highly upregulated in vIL-6-HUVEC and 
demonstrate that stable expression of this viral protein in endothelial cells results in an increase 
Figure 2.7 ITGB3 contributes to vIL-6-induced tubule formation of endothelial cells.  
(A) Representative images from four experiments in duplicates done with EV- and vIL-6- 
HUVEC treated with siRNAs against non-targeting or ITGB3. The center of the images was 
zoomed in for a better resolution of the tubules. (B) The average number of branching points 
per well (4-5 frames/well) in duplicates was calculated and represented in the scatter plot 
graph. **P < 0.01. 
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of total and cellular-surface-targeted ITGB3 protein (Figure 2.8). Interestingly, the levels of 
ITGB3 gene expression in the vIL-6-HUVEC were similar to what DiMaio and colleagues 
detected following KSHV infection of endothelial cells (122) despite the generally low levels of 
vIL-6 expression seen upon infection. To our surprise, the induction of the lytic life cycle, 
which significantly increased vIL-6 expression, did not affect the levels of ITGB3 in KSHV-
infected cells. We hypothesized that this is due to the persistent activation of STAT3 in latently 
Figure 2.8 Model of vIL-6 induction of ITGB3. 
Expression of vIL-6 augments JAK/STAT3 activation increasing the levels of ITGB3, which 
results in higher surface expression of the heterodimer αVβ3 integrin. This process promotes 
vIL-6-induced endothelial cell adhesion to the ECM components fibronectin and vitronectin 
and promotes tubule formation. Created with Biorender. 
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infected cells (270). Thus, the activation of STAT3 by vIL-6 and other viral factors during 
latency may induce maximal levels of ITGB3 in latently-infected cells.  
We have also demonstrated that vIL-6 is secreted from endothelial, epithelial, and B-
cells, and intercellularly induce ITGB3 at the mRNA and protein levels in naïve endothelial 
cells. Importantly, lytically replicating cells secreted high levels of vIL-6, which induced 
ITGB3 in a paracrine manner. These results are relevant because vIL-6 can be found circulating 
in the blood of KSHV and HIV co-infected individuals (93, 271), and its paracrine signaling is 
believed to play a significant role in viral pathogenesis (67).  
Since vIL-6 is known to induce the activation of the JAK/STAT signaling pathway (89, 
265), we sought to determine if this pathway is involved in ITGB3 induction. First, we found, as 
has been shown in other cell types (206, 207), that vIL-6 co-immunoprecipitates with gp130 in 
HUVEC and that siRNA-mediated knockdown of gp130 reduced vIL-6-induced activation of 
STAT3 and ITGB3 expression. Additionally, we found that phosphorylated STAT3 is required 
for vIL-6 specific induction of ITGB3. To our knowledge, this is the first report to demonstrate 
a mechanism of ITGB3 expression that requires STAT3 signaling.  
Furthermore, neither overexpression of the cellular IL-6 homolog nor treatment with 
recombinant hIL-6 in endothelial cells induced ITGB3 expression. A possible explanation for 
this result is that HUVEC are more responsive to hIL-6 trans-signaling activation that relies on 
the binding of the cytokine to soluble, rather than to membrane-bound, IL-6Rα (267, 268). 
Despite the slight activation of STAT3, levels of ITGB3 were not increased in the presence of 
hIL-6. Importantly, this was circumvented when cells were supplemented with a recombinant, 
soluble IL-6Rα that increased the levels of ITGB3 to levels seen in vIL-6-expressing cells, 
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confirming that induction of the pathway plays a significant role in modulating the expression 
of ITGB3. In our studies, activation of STAT3 signaling by hIL-6 alone in endothelial cells is 
not sufficient for ITGB3 induction, suggesting that vIL-6 overcomes the need for IL-6Rα by 
consistently activating the pathway through gp130. Given that sIL-6R can be found circulating 
in human blood (267) and KSHV-infected individuals have high levels of circulating viral and 
cellular IL-6, we speculate that, in patients, activation of the signaling pathway by both proteins 
may induce the expression of ITGB3. 
Viral IL6-HUVEC treated with a non-targeting siRNA pool have a statistically 
significant higher binding affinity to the ECM proteins fibronectin and vitronectin than do vIL-
6-HUVEC that have ITGB3 knocked down. This significant decrease in binding with ITGB3 
knockdown was unique to the vIL-6-HUVEC compared to EV-HUVEC. Furthermore, utilizing 
these siRNAs, we performed a tubule formation assay, an in vitro approach to measure 
angiogenic phenotype. The vIL-6-HUVEC that still expressed ITGB3 had more branching 
points than either EV-HUVEC or vIL-6-HUVEC treated with the ITGB3 siRNA. The ability of 
vIL-6-HUVEC to have increased binding to fibronectin, which aids in the stability and growth 
of microvessels (272, 273), and increased endothelial cell branching only when ITGB3 is 
expressed, hints at the importance of this induction for angiogenesis. 
Altogether, our data identify the KSHV protein vIL-6 as a bona fide inducer of ITGB3. 
We hypothesize that ITGB3 plays an important role in the capacity of the virus to induce 
angiogenesis and endothelial cell migration. The ability of vIL-6 to be secreted from KSHV-
infected cells to affect cells in a paracrine manner further confirms the essential role that 
infiltrating cells might play in KS lesions by enhancing cellular processes such as angiogenesis. 
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In conclusion, this report further characterizes the role of vIL-6 in endothelial cells and its 
contribution to viral pathogenesis.  
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Lymphomas are a diverse group of neoplastic diseases that arise from lymphoid cells. 
They are subdivided into Hodgkin and non-Hodgkin lymphomas (NHL). Approximately 90% of 
lymphoma cases in the United States are classified as NHL, which are further subclassified into 
>60 subtypes depending on characteristics, such as the cell of origin, stage of cell development, 
and clinical aggressiveness (274). The American Cancer Society predicts that in the United 
States alone, >80,000 patients will receive a NHL diagnoses during 2021 (275). NHL that arises 
from B-cells accounts for up to 90 % of the cases (274). The occurrence of specific lymphomas 
is regionally dependent. For example, some low-income areas have more cases of high-grade 
(aggressive) lymphoma, whereas low-grade (indolent) lymphomas are more common in high-
income countries (274). Many factors influence the incidence of lymphomas, including 
genetics, race, occupation, immune disorders, and infectious agents.  
Infections with certain viruses and bacteria are associated with the development of 
several NHL. Helicobacter pylori is the etiologic agent of most gastric mucosa-associated 
lymphoid tissue lymphomas (276). Furthermore, Borrelia burgdorferi and Chlamydia 
psittascosis are associated with marginal zone lymphoma, whereas Coxiella burnetti is 
 
3 This chapter previously appeared as an article in the journal Frontiers in Oncology. The original citation is as 
follows: Rivera-Soto R, Yu Y, Dittmer DP, Damania B. Combined Inhibition of Akt and mTOR Is Effective 
Against Non-Hodgkin Lymphomas. Frontiers in Oncology (2021) 11(2203). doi: 10.3389/fonc.2021.670275. 
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considered a risk factor for diffuse large B-cell lymphoma (DLBCL) (277-279). As mentioned 
in Chapter 1, seven viruses are associated with human cancers, including hematological 
malignancies. The retrovirus HTLV-1, discovered in the 1980s, is associated with adult T-cell 
leukemia/lymphoma, whereas EBV is linked to several lymphomas, including Hodgkin 
lymphoma, DLBCL, Burkitt’s lymphoma (BL), extranodal NK/T cell lymphoma, and is usually 
present in PEL cells (280, 281). In general, viral-associated lymphomas are considered as 
aggressive.  
Follicular lymphoma (FL) is the second most common NHL and is characterized by a 
nodular pattern of growth and develops in the germinal center of lymph nodes (282). FL is 
believed to arise from the t(14;18)(q32;q21) translocation, which places the anti-apoptotic gene 
BCL-2 under the control of the IgH enhancer leading to its constitutive expression (274, 282). 
Although FL is usually indolent with a median survival of over 15 years, patients also develop 
refractory FL, which is more aggressive. Due to the indolent nature of the disease, most patients 
are diagnosed late, during stage III-IV. The treatment consists of anti-CD20-antibodies, i.e., 
rituximab (R) with or without chemotherapy (e.g., CHOP). The response during the first two 
years of treatment is critical in prognosticating the course of the disease (283). By definition, 
refractory FL no longer responds to CHOP or R-CHOP, and there is a need to develop novel 
therapeutics for these patients. PI3K inhibitors have been approved for the treatment of 
refractory FL, and a recent report demonstrated that the PI3K inhibitor idelalisib reshapes the 
tumor microenvironment leading to a decrease in angiogenesis and by reducing the recruitment 
of regulatory T-cells (284). 
DLBCL is the most common lymphoma in the United States, accounting for 
approximately 24 % of all cases (275). Most DLBCL are classified as either germinal center B-
61 
cell or activated B-cell subtype, based on molecular markers (285). DLBCL is an aggressive 
lymphoma requiring immediate intervention; only about half of the patients respond to R-
CHOP, and more intensive regimens might be more beneficial for patients who can tolerate it 
(274, 285-287). Lymphomas containing mutations involving Myc and BCL2/BCL6 are usually 
termed double-hit lymphomas and tend to be more aggressive. In some situations, EBV 
infections are considered as an additional “hit,” which can worsen the disease outcome (281). 
Although patients with localized DLBCL that respond to treatment have a very good prognosis, 
relapsed patients have the opposite outcome, and there is a need to develop innovative 
therapeutic approaches. DLBCL cells might display deregulated JAK/STAT and 
PI3K/Akt/mTOR signaling, and early clinical studies have shown a benefit from inhibiting 
certain members of the pathway (288-293).  
Primary effusion lymphoma (PEL) is an aggressive post-germinal center B-cell 
lymphoma. It is directly linked to the γ-herpesvirus, Kaposi's sarcoma-associated herpesvirus 
(KSHV; HHV8) (42). PEL is characterized by lymphomatous effusions in body cavities such as 
the peritoneal, pleural, and pericardium that are composed of large plasmablastic cells (65). The 
disease mostly develops in the context of immunosuppression with a median survival of 6 
months (69, 70). PEL are exquisitely dependent on Akt kinase signaling pathways owing to the 
involvement of viral proteins. This motivated us to target this signaling cascade with novel Akt 
inhibitors and explore the efficacy of these agents broadly in NHL. 
The phosphatidylinositol 3‐kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) 
regulates many cellular processes (294-296). Given the significant role that the pathway plays in 
regulating cell survival, proliferation, and metabolism, it is not surprising to see 
PI3K/Akt/mTOR signaling deregulated in many cancers (297, 298). The hyperactivation of the 
62 
pathway can occur through different mechanisms, including mutations or gene amplification of 
the kinases PI3K and Akt (also known as protein kinase B) or the loss of the tumor suppressor 
phosphatase and tensin homolog (PTEN) (23, 24). Viral proteins also activate this pathway 
substituting for genetic lesions, specifically in PEL (39). Given that multiple NHL subtypes 
display activated PI3K/Akt/mTOR signaling, members of the pathway have become attractive 
drug targets. Several compounds advanced through clinical development, e.g., duvelisib, 
copanlisib, and idelalisib in the treatment of refractory FL, underscoring the clinical 
significance of targeting this pathway (290, 299-302).  
Idelalisib and rapamycin-derivatives (sirolimus) target PI3K and mTOR, but the 
identification and development of inhibitors for the other kinase in this pathway, Akt, has 
proven difficult. Recently, two novel pan-Akt inhibitors, miransertib (MK-7075/ARQ 092) and 
MK-4440 (ARQ 751) have been reported (303). Both compounds are highly specific allosteric 
inhibitors that target all three Akt isoforms with an inhibitory concentration (IC50) as low as 1 
nM against purified kinase, and both are orally bioavailable (304). We sought to test these 
inhibitors against several subtypes of NHL. Our results show that both compounds effectively 
reduce the viability of several NHL cell lines. Moreover, a combination of miransertib with the, 
likewise allosteric and orally bioavailable, mTORC1 inhibitor sirolimus (rapamycin) resulted in 
a reduction in tumor growth in four different xenograft models. Overall, this study demonstrates 
that targeting Akt and mTOR with two individual inhibitors is a feasible approach against these 
malignancies and warrants clinical development.  
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MATERIALS AND METHODS 
CELL CULTURE 
All non-Hodgkin lymphoma cell lines were cultured on RPMI 1640 (Corning) 
supplemented with 10% heat-inactivated FBS, 1% penicillin/streptomycin, and 1% L-
glutamine. All PEL cells were maintained as described above but further supplemented with 
0.075% sodium bicarbonate (Gibco) and 0.05 mM β-mercaptoethanol (Gibco). The human 
peripheral blood B-cells were purchased from STEMCELL Technologies. Regular mycoplasma 
testing is performed on the cell lines. Cell lines were authenticated by high-throughput 
sequencing. 
COMPOUNDS 
 ArQule, Inc. (a wholly owned subsidiary of Merck & Co., Inc.) provided miransertib 
(ARQ 092) and MK-4440 (Figure 3.1A). Miransertib and dactolisib were also purchased from 
MedChemExpress. For in vitro studies, both compounds were dissolved to 30 mM in DMSO 
and stored at -20°C protected from light. Sirolimus (rapamycin) was purchased from 
Selleckchem, dissolved to 10 mM in DMSO, and stored at -80°C (Figure 3.1B). For the in vivo 
studies, twice per week, miransertib was dissolved to 10 mg/ml in 0.01 M phosphoric acid (pH 
2.2) and protected from light. Sirolimus was dissolved to 10 mg/ml in 100% ethanol and further 
diluted on the day of administration to equal parts of 20% polyethylene glycol-400 and 20% 
Tween-80 in water (305).  
64 
IMMUNOBLOTTING 
Cells were collected, and lysates were prepared from washed pellets using 
Radioimmunoprecipitation assay lysis buffer (1% NP-40, 150 mM NaCl, 50 mM Tris HCl pH 
8.0, 5 mM EDTA, 0.5% Sodium deoxycholate, 0.1% SDS). Lysates from tumors were prepared 
by homogenizing frozen slices with T-PER® Tissue Protein Extraction Reagent 
(ThermoScientific) according to the manufacturer's instructions. Lysis buffers were 
supplemented with Halt protease/phosphatase inhibitor cocktail (ThermoScientific). Samples 
were clarified by centrifugation at 16,000 x g for 10-15 minutes, and protein concentration was 
determined by Bradford (Bio-Rad) or Pierce BCA (ThermoScientific) assays. Lysates were 
loaded with 4x Laemmli sample buffer (Bio-Rad), resolved on acrylamide SDS-PAGE gels, and 
transferred onto a nitrocellulose membrane (Amersham). For the pAkt (T308) immunoblots, 
cells were lysed in 1x Laemmli buffer (2% SDS, 10% glycerol, 60 mM Tris-HCl pH 6.8, 0.01% 
bromophenol blue, 100 mM DTT, 6 M urea, and 5% 2-mercaptoethanol), sonicated for 15s 
(4.5s on, 0.5s off, 10% amplitude), and boiled at 100°C for 10 min (306). Primary antibodies 
against pAkt [(S473; 4060) and (T308; 13038S)], Akt (9272), pFOXO1 (S256; 84192), FOXO1 
(2880), pS6K (T421/S424; 9204), S6K (9202), pS6 (S235/6; 4858), S6 (2217), PARP (9542), 
cleaved-caspase-3 (9664), cleaved-caspase-7 (9491), and α-tubulin (9099) were purchased from 
Figure 3.1 Akt and mTORC1 inhibitors.  
Chemical structures of miransertib (A) and sirolimus (B). 
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Cell Signaling Technologies (CST). All primary antibodies were used at a dilution of 1:1000, 
except for pS6, S6, and tubulin, which were used at a dilution of 1:4000-5000. The HRP-
conjugated primary antibody against β-actin (sc-47778 HRP) was purchased from Santa Cruz 
Biotechnology and used at a 1:5000-10000 dilution. The secondary HRP-conjugated anti-rabbit 
(7074) antibody was purchased from CST and used at a 1:2000-5000 dilution. 
CELLTITER-GLO CELL VIABILITY ASSAY 
One hundred microliters of a suspension of 1.6 x 105 cells/ml were seeded into a 96-well 
white plate (Greiner Bio-One). Cells were treated with compounds for up to 72 h, and CellTiter-
Glo (Promega) was used to determine cell viability according to the manufacturer's protocol. 
Luminescence was measured in a CLARIOstar plate reader (BMG Labtech). All data points 
were collected in triplicates from at least three experiments.  
MTS CELL PROLIFERATION ASSAY 
 One hundred microliters of a suspension of 1.6 x 105 cells/ml were seeded into a 96-well 
plate and treated with compounds for up to 72 h. Cells were then subjected to the CellTiter 96® 
AQueous One Solution Cell Proliferation Assay according to the manufacturer’s protocol 
(Promega). Absorbance was measured in a CLARIOstar plate reader (BMG Labtech). All data 
points were collected in triplicates from at least three experiments. 
TRYPAN BLUE EXCLUSION ASSAY  
One milliliter of 1.6 x 105 cells/ml was plated in 24-well plates and treated with 
compounds for up to 72 h. The number of live cells was manually counted by excluding dead 
cells (stained with trypan blue) using a hematocytometer. All data points on NHL cells were 
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collected in duplicates from at least three experiments. The experiments with primary cells were 
done with 3-6 biological replicates.  
CASPASE-3 ACTIVITY ASSAY 
A maximum of 2 x 106 cells in 10 ml of total media was treated for 48-72 h, and the 
activity of caspase-3 was measured by using ApoAlert Caspase-3 Fluorescent Assay Kit 
(Takara Bio) according to the manufacturer's instructions. Fluorescence was measured in a 
CLARIOstar plate reader (BMG Labtech). All data points were collected from at least three 
experiments.  
ANNEXIN-V AFFINITY ASSAY 
Two million cells diluted at a concentration of 2 x 105 cells/ml were treated for 48 h. 
Four hundred thousand cells were washed twice with 200 μl of FACS buffer (0.5% BSA in 
PBS) and stained with annexin-V antibodies conjugated to fluorescein isothiocyanate (FITC) 
and propidium iodide dye according to the manufacturer's instructions (Biolegend). Samples 
were processed on a MACSQuant VYB flow cytometer (Miltenyi Biotec). The analysis was 
conducted using FlowJo software. 
XENOGRAFT MODELS 
All animal studies were performed under protocols approved by the University of North 
Carolina Institutional Animal Care and Use Committee. 
PEL model. Four to five weeks old female NOD-scid-gamma (NSG) mice were 
intraperitoneally (i.p.) injected with 200 µl of PBS containing 1.0 x 105 BCBL-1-Trex-RTA-
Luciferase cells. After three days, a total of 24 mice were randomly sorted into four study arms, 
vehicle, miransertib, sirolimus, and the combination of miransertib and sirolimus. Treatment 
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began on day three after injection. Two hundred microliters of miransertib or the vehicle for 
miransertib were administered via oral gavage daily (Monday-Friday) to a final dose of 100 
mg/kg of body weight. One hundred microliters of sirolimus or the vehicle for sirolimus were 
administered through i.p. injection twice a week (Monday and Thursday) to a final dose of 
0.375 mg/kg of body weight. Once a week and before dosing, imaging was performed using the 
Xenogen IVIS-Lumina System (Caliper Life Sciences) by administering, through i.p. injection, 
10 μl/gbw of luciferin (PerkinElmer). Images were analyzed using Living Image v4.4. All 
animals were sacrificed when the tumor burden reached institutional limits (Figure 3.2).  
BJAB and Karpas-422 model. Four to five weeks old female NSG mice were 
subcutaneously (s.c.) injected with 2.0 x 105 (BJAB) or 2.5 x 106 (Karpas-422) cells in 200 μl of 
a 1:1 mixture of PBS and Matrigel (Corning). For the BJAB experiment, High-Concentration 
Matrigel was used. Tumor volume was measured thrice per week using calipers. Once tumors 
were palpable, mice were randomly assigned to four treatment groups and treated following the 
Figure 3.2 Experimental design for BCBL1 xenograft model.  
One hundred thousand cells were injected i.p. on a Friday. Three days later, the dosing started 
with 100 mg/kg of miransertib (p.o.; 5x week) or 0.375 mg/kg of sirolimus (i.p. 2x week). 
Images were obtained on Mondays. 
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same schedule as above. The experiments were ended, and animals were sacrificed when the 
tumor volume reached institutional limits.  
FL-18 model. Four to five weeks old female NSG mice were i.p. injected with 200 μl of 
anti-asialo GM1 antibody (WAKO) that was freshly reconstituted in 6.67 ml of PBS. Twenty-
four hours later, 1 x 106 FL-18 cells (200 μl) in a 1:1 mixture of PBS and Growth Factor 
Reduced Matrigel (Corning) were s.c. injected. Tumor volume was measured as above. 
Treatments and harvesting were performed as above.  
IMMUNOHISTOCHEMISTRY 
  Solid tumors were fixed in 10% formalin vials (Fisher Scientific) for up to 3 days, and 
sections were processed as previously (307). The pS6 primary antibody was purchased from 
CST (4858) and used at a dilution of 1:400. The images were obtained with a Leica Microscope 
(DM4000B) and Zeiss camera (Axiocam 105) and acquired using Zeiss Zen Core. Images were 
analyzed as in Appendix 3 to calculate the H-index using the Multiplex IHC module from 
HALO (Indica Labs).  
COMPUSYN 
To assess the effect of combining miransertib and sirolimus, the combination index (CI) 
was calculated using the Chou-Talalay method (308). The CI was obtained using CompuSyn 
(http://www.combosyn.com/) according to their instructions. A synergistic effect was 
determined when the calculated CI at a Fa50 (effect level of 50%) was <1.0.  
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STATISTICS 
All statistical tests were performed using GraphPad Prism8. The EC50 was calculated 
using the log(inhibitor) vs. response - Variable slope (four parameters) function of GraphPad 
with the data collected after 72 h treatment. 
 
RESULTS 
FOLLICULAR LYMPHOMA CELL LINES ARE SENSITIVE TO AKT INHIBITORS.  
To assess the effect of the Akt inhibitors miransertib and MK-4440, we treated a 
representative FL cell line, FL-18, for 72 h and manually counted live cells using trypan blue. 
Both compounds reduced the number of live cells in a dose-dependent manner (Figure 3.3A). 
To determine the half-maximal effective concentration (EC50), we performed CellTiter-Glo 
assays. Treatment with both inhibitors reduced the viability in a dose-dependent manner (Figure 
3.3B). Table 3.1 shows the calculated EC50 obtained from the drug response curves. These 
results indicate that both compounds were active against FL.  
To confirm that miransertib and MK-4440 inhibit Akt and its downstream targets, we 
performed immunoblotting of protein lysates collected from FL-18-treated cells. These 
inhibitors prevent Akt from localizing to the plasma membrane blocking its phosphorylation 
(304). Therefore, we predicted that treatment with the inhibitors would reduce phosphorylation 
of Akt and its downstream targets, FOXO1, S6K, and S6. Both S6K and S6 are downstream of 
mTORC1, whereas FOXO1 is a direct Akt target. Both inhibitors effectively reduced the levels 
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of pAkt in FL-18 cells (Figure 3.3C and D). Furthermore, both inhibitors effectively decreased 
pFOXO1, pS6K, and pS6, demonstrating that the Akt inhibitors repress the mTORC1 and 
FOXO1 arms of the PI3K/Akt/mTOR signaling pathway. Washout experiments showed that the 
Figure 3.3 Follicular lymphoma cells are sensitive to Akt inhibition.  
(A) The follicular lymphoma (FL) cell line FL-18 was treated for 72 h with miransertib or MK-
4440, and live cells were counted by excluding dead cells stained with trypan blue. (B) Two FL 
cell lines, FL-18 (i) and SU-DHL-16 (ii), were treated as in panel A, but viability was 
measured using CellTiter-Glo. (C) FL-18 cells were treated with 1 or 5 µM of miransertib or 
MK-4440 for up to 72 h. Immunoblots were performed to determine the levels of 
phosphorylated (p)Akt (S473), pFOXO1 (S256), p-p70-S6K (T421/S424), pS6 (S235/6), the 
respective total proteins, and the loading control β-actin. The red arrow points to the p70-S6K 
isoform. (D) FL-18 cells were treated with 1 or 5 µM of miransertib or MK-4440 for 24 h. 
Immunoblots were performed to determine the levels of pAkt (T308), Akt, and the loading 
control α-tubulin. 
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inhibition lasts longer in cells treated with MK-4440 (Appendix 4). Together, these results 
indicate that in FL cells, both Akt inhibitors can decrease the activity of the pathway and reduce 
cell viability. 
Table 3.1 Summary of EC50 for miransertib and MK-4440 calculated in a variety of NHL 
cell lines. 
  EC50 (µM) 
 Cell Line Miransertib MK-4440 
Follicular 
Lymphoma 
FL-18 0.573 2.46 





BJAB 1.06 1.08 
SU-DHL-4 0.080 0.007 
Karpas-422 0.124 0.012 




BC-1 0.837 1.19 
BC-3 4.24 3.53 
BCBL-1 2.28 1.53 
JSC-1 2.33 2.19 
VG-1 0.567 0.258 
Mantle Cell 
Lymphoma 
Granta-519 2.48 25.77 
Jeko-1 4.46 13.0 
JVM-2 0.817 0.382 
Rec-1 4.84 12.7 
Burkitt’s 
Lymphoma 
BL-41 1.07 0.711 
Daudi 0.42 1.43 
Ramos 4.23 3.78 
Raji 2.55 18.0 
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INHIBITION OF AKT AND mTORC1 IS SYNERGISTIC AGAINST FOLLICULAR 
LYMPHOMA. 
Targeting multiple signaling pathways or several members of the same pathway is a 
common strategy aimed at reducing the chances of developing drug resistance (309). Although 
we were able to effectively see a reduction in the viability of cells treated with either 
miransertib or MK-4440, we wanted to know whether the addition of the mTOR inhibitor, 
sirolimus, would be synergistic. Thus, we measured the viability of FL-18 cells treated with the 
single compounds miransertib, MK-4440, sirolimus, or the combination of the Akt and the 
mTORC1 inhibitor (Figure 3.4A). As expected, individual treatment with the three single agents 
reduced the proliferation of the FL-18 cells. The effect was further enhanced when the Akt and 
mTORC1 inhibitors were combined. The combination of either miransertib or MK-4440 with 
sirolimus was strongly synergistic (CI<0.2), according to the Chou-Talalay method (308). For 
further experiments, we chose to focus on miransertib because it is further along in clinical 
development.  
Another reason to focus on the miransertib/sirolimus combination was the feedback 
activation of Akt by mTOR. During long, continuous exposure, inhibition of mTORC1 
increases the activity of Akt through mTORC2-mediated phosphorylation of serine 473, leading 
to an increase in activated Akt (23, 310). We predicted that targeting both Akt and mTORC1 
would strongly hinder the activation of the overall pathway. To prove this hypothesis, we 
performed immunoblots for key members of the pathway in lysates collected from singly and 
dually-treated cells. Treatment with miransertib prevented phosphorylation of Akt and reduced 
the levels of pS6 (Figure 3.4B and Appendix 5). As expected, sirolimus-mediated inhibition of 
mTORC1 strongly decreased the levels of pS6 while having no affect on pAkt. When cells were  
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Figure 3.4 Combined inhibition of Akt and mTORC1 strongly suppresses the growth of 
follicular lymphoma cells.  
(A) FL-18 cells were treated with different doses of sirolimus alone or in combination with 
miransertib (i) or MK-4440 (ii). After 72 h, the percentage of viable cells was calculated using 
CellTiter-Glo, normalized to the DMSO (vehicle; 100%) control. (B) FL-18 cells were treated 
for 3 h with miransertib, sirolimus, or the combination of both, and immunoblots performed as 
in Figure 1C. (C) FL-18 cells were subcutaneously (s.c.) injected into NOD-scid-gamma 
(NSG) mice and treated with vehicle (n=6), 100 mg/kg miransertib (n=6), 0.375 mg/kg 
sirolimus (n=6), and 100 mg/kg miransertib + 0.375 mg/kg sirolimus (n=6). The tumor growth 
was measured thrice per week, and the mean ± STD was illustrated in the line graph. **p<0.01 
determined by two-way ANOVA. (D) Immunoblots were performed on proteins extracted from 
the tumors collected at the end of the experiment shown in panel C. (E) Representative images 
of immunohistochemistry against pS6 (S235/6) performed to tumor sections. Sections were 
developed with DAB (3,3′-diaminobenzidine) and counterstained with hematoxylin. (Scale 
bars, 100 μm) (F) The histo (H)-score of pS6 was calculated from 9 frames per treatment group 
using HALO. *p<0.05; ***p<0.001 determined by one-way ANOVA. 
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treated with both inhibitors, both pAkt and pS6 were reduced. These results demonstrate the 
superiority of combined inhibition of Akt and mTORC1, which efficiently dampens the entire 
signaling network.  
Next, we tested these inhibitors in vivo. NOD-scid gamma (NSG) mice were 
subcutaneously (s.c.) injected with FL-18 cells. Once the tumors were palpable, mice were 
treated for three weeks. Treatment with miransertib or sirolimus individually or the combination 
of both compounds significantly reduced tumor growth (Figure 3.4C). There was no difference 
between the groups treated with the monotherapy versus the group treated with the combination. 
Additionally, we measured the animal weight throughout the experiment to assess the well-
being of the animals and determine any in vivo toxicity (Appendix 6). At the end of the 
experiment, tumor sections were lysed, and immunoblotting was performed to verify that the 
compounds inhibited their target in vivo. Treatment with miransertib, but not sirolimus, reduced 
the levels of pAkt (Figure 3.4D). Furthermore, immunoblots showed that the levels of pS6 were 
reduced in both miransertib- and sirolimus-treated groups and more completely suppressed in 
tumors of mice treated with both compounds. Similarly, immunohistochemistry for pS6 
performed on tumor sections confirmed a significant reduction in the group treated with the Akt 
inhibitor alone or in combination with sirolimus (Figure 3.4E and F, and Appendix 7). These 
studies demonstrate that in the FL-18 xenograft model, miransertib and sirolimus inhibit their 
targets and strongly suppress tumor growth. 
COMBINED TREATMENT OF MIRANSERTIB AND SIROLIMUS REPRESSES THE 
GROWTH OF DIFFUSE LARGE B-CELL LYMPHOMA. 
To determine whether this approach was effective in other subtypes of NHL, we tested 
our Akt inhibitors against multiple DLBCL cell lines. We treated four different cell lines, 
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including BJAB and Karpas-422, with a broad range of concentrations for up to 72 h and 
performed CellTiter-Glo assays. Miransertib and MK-4440 individually reduced DLBCL 
viability in a cell line-dependent manner (Figure 3.5A and Table 3.1). Immunoblots with lysates 
from a representative DLBCL cell line, BJAB, also showed that treatment with either inhibitor 
sharply reduced the levels of pAkt while only slightly reducing the downstream targets, 
pFOXO1, pS6K, and pS6 (Figure 3.5B and C, and Appendix 4).  
 
Figure 3.5 Diffuse large B-cell lymphoma cells are sensitive to Akt inhibition by 
miransertib and MK-4440.  
(A) The DLBCL cell lines BJAB (i), Karpas-422 (ii), and SU-DHL-4 (iii) were treated for 72 h 
with miransertib, or MK-4440, and CellTiter-Glo was used to measure viability. (B-C) BJAB 
cells were treated for up to 72 h with miransertib, sirolimus, or the combination of both, and 
immunoblots performed as in Figure 3.3C. The red arrow points to the p70-S6K isoform. 
76 
The differences in reducing the phosphorylation between pAkt and its downstream 
targets suggest that although Akt is inhibited, the pathway was not entirely repressed. To 
determine whether combining the Akt inhibitors with the mTORC1 inhibitor, sirolimus, would 
be effective, BJAB cells were treated for 72 h with single compounds or their combination. 
Miransertib and MK-4440 each reduced viability to as low as 29% when compared with DMSO 
(Figure 3.6A). Sirolimus reduced the growth of BJAB cells as well. The combination of either 
miransertib or MK-4440 with sirolimus was strongly synergistic, with a CI below 0.2. 
Combining miransertib with sirolimus completely abrogated the phosphorylation of both Akt 
and S6 (Figure 3.6B and Appendix 5). BJAB serves as an example of an extremely robust 
DLBCL. These results suggest that for such tumor subtypes, the combined inhibition of Akt and 
mTORC1 is needed to shut down the PI3K/Akt/mTOR network. Furthermore, although 
treatment with sirolimus increased the levels of pFOXO1, this was circumvented when cells 
were treated with the combination (Figure 3.6C). 
Next, we tested these compounds in vivo using two DLBCL xenograft models. NSG 
mice were s.c. injected with BJAB or Karpas-422 cells. Treatments began once the tumors were 
palpable and continued until the tumor masses reached institutional limits. The combined Akt 
and mTORC1 inhibitors treatment inhibited BJAB tumor growth compared with the vehicle or 
the monotherapy (Figure 3.6D and Appendix 6). BJAB tumors were subjected to 
immunohistochemistry and immunoblotting, which showed that treatment with miransertib 
alone or in combination with sirolimus reduced the levels of both pAkt and pS6 (Figure 3.6E-G 
and Appendix 8). 
Like the BJAB xenograft, treatment with miransertib and sirolimus reduced Karpas-422 
tumor growth (Figure 3.6H). Treatment with miransertib alone reduced tumor growth but did  
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Figure 3.6 Combined inhibition of Akt and mTORC1 suppresses the growth of diffuse 
large B-cell lymphoma.  
(A) BJAB cells were treated with different doses of sirolimus alone or in combination with  
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not reach statistical significance despite a significant reduction in the levels of pAkt (Figure 
3.6I). By contrast, the combination of miransertib and sirolimus strongly and significantly 
reduced tumor growth and decreased the activation of the pathway as seen by immunoblotting 
(Figure 3.6I) and immunohistochemistry (Figure 3.4J and K, and Appendix 9). These results 
suggest that while DLBCL are sensitive to Akt inhibition by miransertib, more complete 
therapeutic efficacy is achieved in combination with an mTORC1 inhibitor. 
MIRANSERTIB AND MK-4440 REPRESS THE GROWTH OF KSHV-ASSOCIATED 
PRIMARY EFFUSION LYMPHOMA.  
Primary effusion lymphoma (PEL) is a rare but highly aggressive NHL linked to the γ-
herpesvirus Kaposi's sarcoma-associated herpesvirus (KSHV) (42). The activation of the 
PI3K/Akt/mTOR signaling pathway is essential for PEL (39, 305, 311, 312). Notably, the 
KSHV proteins ORF K1, viral G-protein-coupled receptor, and viral interleukin-6 induce the 
miransertib (i) or MK-4440 (ii). After 72 h, the percentage of viable cells was calculated using 
CellTiter-Glo, normalized to the DMSO (vehicle; 100%) control (B) BJAB cells were treated 
for 3 h with miransertib, sirolimus, or the combination of both, and immunoblots performed as 
in Figure 3.3C. (C) BJAB cells were treated for 48 h with DMSO, miransertib (5 µM), 
sirolimus (5 nM), or the combination of miransertib and sirolimus. Lysates were prepared and 
immunoblots were performed as in Figure 3.4B. (D) BJAB cells were s.c. injected into NSG 
mice, followed by treatment with vehicle (n=6), 100 mg/kg miransertib (n=6), 0.375 mg/kg 
sirolimus (n=6), and 100 mg/kg miransertib + 0.375 mg/kg sirolimus (n=6). The tumor growth 
was measured thrice per week, and the mean ± STD was illustrated in the line graph. *p<0.05 
determined by two-way ANOVA. (E) Immunoblots were performed from protein extracted 
from the tumors collected at the end of the experiment shown in panel D. (F) Representative 
immunohistochemistry images against pS6 (S235/6) performed to tumor sections as in Figure 
3.4E. (G) The H-score of pS6 was calculated from 8 frames per treatment group using HALO. 
*p<0.05; ***p<0.001 determined by one-way ANOVA (H) Xenograft with Karpas-422 was 
performed as in panel D. *p<0.05; **p<0.01 determined by two-way ANOVA. (I) Similar to 
panel E but with samples collected from the experiment shown on panel H. (J) Representative 
images of immunohistochemistry against pS6 (S235/6) performed in tumor sections as in 
Figure 3.4F. (Scale bars, 100 μm) (K) The H-score of pS6 was calculated from 12 frames per 
treatment group using HALO. *p<0.05; ***p<0.001; ****p<0.0001 determined by one-way 
ANOVA. 
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activation of this signaling pathway. Since most PEL cell lines do not display PI3K activating 
mutations, viral proteins are hypothesized to drive the constitutive activation of the pathway 
(66). We treated a panel of PEL cells with miransertib or MK-4440 and counted live cells by 
excluding dead cells stained with trypan blue. Treatment with the inhibitors suppressed growth 
with none to minimal cells alive at 10 µM (Figure 3.7A and Appendix 10). To test a broader 
range of concentrations and to calculate the EC50, we used CellTiter-Glo following a 72-h 
incubation with the inhibitors. The response to the compounds was complete but varied across 
different PEL cell lines (Figure 3.7B and Table 3.1). These results demonstrate that Akt 
inhibitors repress PEL cell growth.  
Immunoblots were performed to determine if the compounds were inhibiting their 
predicted molecular targets. Treatment of BC-3 cells with either compound for 24 h strongly 
reduced the phosphorylation of Akt but had only minimal effect on the downstream targets 
pFOXO1, pS6K, and pS6 (Figure 3.7C). This was surprising and underscored the need in 
certain NHL for inhibiting multiple steps in the same pathway. 
MIRANSERTIB SYNERGIZES WITH SIROLIMUS TO REDUCE TUMOR GROWTH 
IN A PEL XENOGRAFT MODEL. 
The previous observations suggested that in the PEL subtype of DLBCL, even though 
Akt was inhibited, the pathway remained active. To overcome this barrier, we tested whether 
the combination of inhibitors has a synergistic effect on viability. A representative PEL cell 
line, BCBL-1, was treated with a range of concentrations of either miransertib, MK-4440, 
sirolimus, or the combination of sirolimus and the Akt inhibitor. Both Akt inhibitors reduced 
viability compared to DMSO (Figure 3.8A), as did sirolimus, but the reduction by the single 
agent was moderate (~ 50%). In contrast, when miransertib or MK-4440 was combined with 
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sirolimus, viability reduced by up to 83% after 72 h of treatment. The calculated CI was below 
0.2, suggesting that the combination was strongly synergistic. The cell viability results were 
mirrored by the molecular target analyses. The addition of sirolimus led to a complete reduction 
in pS6 and in combination with miransertib reduction in pAkt (Figure 3.8B).  
Figure 3.7 Inhibition of Akt by miransertib or MK-4440 reduces the viability of primary 
effusion lymphoma cells.  
(A) The PEL cell lines BC-1 (i), BC-3 (ii), BCBL-1 (iii), JSC-1 (iv), VG-1 (v) were treated for 
72 h with miransertib, or MK-4440, and live cells were counted by excluding dead cells stained 
with trypan blue. (B) The PEL cell lines BC-1 (i), BC-3 (ii), BCBL-1 (iii), JSC-1 (iv), VG-1 (v) 
were treated for 72 h with miransertib, or MK-4440, and CellTiter-Glo was used to measure 
viability. (C) A representative PEL cell line, BC-3, was treated for 24 h with miransertib or 




(A) BCBL-1 cells were treated with different doses of sirolimus alone or in combination with 
miransertib (i) or MK-4440 (ii). After 72 h, the percentage of viable cells was calculated using 
CellTiter-Glo, normalized to the DMSO (vehicle; 100%) control. (B) BC-3 cells were treated 
for 6 h with DMSO, MK-4440 (1.5 µM), miransertib (1.5 µM), sirolimus (5 nM), or the 
combination of the mTORC1 and Akt inhibitors. Lysates were prepared and immunoblots were 
performed as in Figure 3.4B. (C) BCBL-1-Luc we intraperitoneally (i.p.) injected into NSG 
mice and treated with vehicle (n=6), 100 mg/kg miransertib (n=6), 0.375 mg/kg sirolimus 
(n=6), and 100 mg/kg miransertib + 0.375 mg/kg sirolimus (n=6) over a course of 4 weeks. 
Figure 3.8 Combined inhibition of Akt and mTORC1 is synergistic against primary 
effusion lymphoma cells.  
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To determine if the Akt inhibitor miransertib alone or combined with sirolimus can 
attenuate tumor growth in vivo, we used a PEL xenograft model. To gain more granularity, we 
followed tumor growth over time using cells expressing a luciferase gene. TRex-RTA BCBL-1 
cells were intraperitoneally (i.p.) injected into NSG mice, allowing us to visualize the tumor 
growth upon injection of luciferin (307, 313). After four weeks of treatment, the combination of 
miransertib and sirolimus significantly reduced growth compared to the vehicle (Figure 3.8C 
and D). At the concentrations used, the single agents did not retard growth, mirroring the results 
from tissue culture experiments. Generally, animals did not show signs of toxicity and did not 
suffer weight loss (Figure 3.8E). Tumors collected from mice treated with the combinatorial 
treatment had lower levels of pS6 (Figure 3.8F-H and Appendix 11). Overall, these results 
suggest that the combined inhibition by miransertib and sirolimus is needed to effectively 
inhibit aggressive NHL, such as PEL.  
MIRANSERTIB AND MK-4440 INDUCE APOPTOSIS IN NHL CELLS. 
The studies presented above demonstrate that inhibition of Akt with miransertib or MK-
4440 reduces the growth of NHL. To determine whether treated cells died or were simply 
growth-arrested, we measured apoptosis. First, a caspase-3 assay to measure the protease 
activity was performed. The results show that treatment for 48-72 h with either miransertib or 
The expression of luciferase was measured every Monday by i.p. injecting mice with luciferin. 
Representative images obtained on the 28th day of treatment show the tumor burden. (D) The 
luminescence measured from panel C images was presented as a box and whiskers plot with 
the whiskers marking the minimum and maximum values. *p<0.05 determined by two-way 
ANOVA. The p-values for all other comparisons were >0.05. (E) The body weight of mice was 
measured and recorded throughout the experiment. (F) Immunoblots were performed from 
protein extracted from the tumors collected at the end of the xenograft experiment shown on 
panels C and D. (G) Representative images of immunohistochemistry against pS6 (S235/6) 
performed to tumor sections as in Figure 3.4E. (Scale bars, 100 μm) (H) The H-score of pS6 
was calculated from at least 15 frames per treatment group using HALO. *p<0.05 determined 
by one-way ANOVA. 
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MK-4440 increased the levels of active caspase-3 in FL-18- (i), BJAB- (ii), and BCBL-1- (iii) 
treated cells (Figure 3.9A). To complement the caspase-3 activity assays, we performed 
immunoblots to determine the levels of cleaved caspase-3 and an additional protein, poly (ADP-
ribose) polymerase (PARP), which cleaved during the induction of apoptosis and thus serves as 
an apoptotic marker (Figure 3.9 and Appendix 12). Similar to the results from the caspase-3 
assay, inhibition of Akt led to an increase in the cleavage of PARP in all three lymphoma 
subtypes (Figure 3.9B). These results suggest that both Akt inhibitors induce apoptosis in NHL 
cells.  
Furthermore, our previous observations suggested that the combination of miransertib 
and sirolimus is strongly synergistic in reducing the viability of several NHL cell lines. 
Therefore, we asked whether the combination had a more robust induction of apoptotic 
signaling. First, we used flow cytometry to quantify the percentage of cells staining for the 
apoptotic marker, annexin-V. Interestingly, although treatment with miransertib increased the 
numbers of cells staining for annexin-V, statistical significance was only attained when cells 
were treated with both Akt and mTORC1, even though sirolimus alone is not an inducer of 
apoptosis (Figure 3.9C). This observation prompted us to determine the activity of caspase-3 in 
cells treated with miransertib and sirolimus. We found that in BJAB and BCBL-1 cells, the 
combination increased caspase-3 activity compared to the single compounds (Figure 3.9D). In 
the case of FL-18 cells, the combination did not increase the activity beyond the levels seen 
with miransertib alone. Interestingly, immunoblots demonstrated that in cells treated with the 
combination of miransertib and sirolimus, there is an increase in the levels of cleaved PARP 
(Figure 3.9E) and cleaved caspase-7 (Figure 3.9F). Altogether, these results suggest that the 
reduction in viability is mediated in part via apoptosis. 
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Figure 3.9 Inhibition of Akt by miransertib or MK-4440 induces apoptosis in non-Hodgkin 
lymphoma cell lines.  
(A) FL-18 (i), BJAB (ii), and BCBL-1 (iii) cells were treated for up to 72 h with DMSO, 
miransertib, or MK-4440 at the indicated concentrations. The level of caspase-3 activity 
following the drug treatment was measured using the ApoAlert Caspase-3 Fluorescent Assay, 
and the results were graphed as a dot plot representing the increase in activity compared to 
DMSO (activity = 0). (B) FL-18, BJAB, and BC-3 cells were treated for 72 h with DMSO, 
miransertib, or MK-4440 at the indicated concentrations. Immunoblots were performed to 
detect the levels of PARP and the loading control β-actin. The red arrow points to cleaved 
PARP. (C) FL-18, BJAB, and BCBL-1 cells were treated for 48 h with vehicle, miransertib (5 
µM for BJAB and BCBL-1, and 10 µM for FL-18), sirolimus (10 nM) or the combination of 
the Akt and mTORC1 inhibitor at the indicated concentrations. The percentage of annexin V+ 
cells was determined by staining cells with annexin V-FITC and propidium-iodide (PI) 
followed by flow cytometry analysis. The mean ± STD of 3 experiments is depicted in the bar 
graph. *p<0.05; **p<0.01; ***p<0.001 determined by one-way ANOVA. (D) FL-18, BJAB, 
and BCBL-1 cells were treated for 48-72 h with vehicle, miransertib (1 µM for BJAB and 
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MIRANSERTIB AND MK-4440 ARE NOT TOXIC TO PRIMARY HUMAN B-CELLS.  
Finally, we wanted to determine the effect of the compounds on normal (non-cancerous) 
cells. To test whether the compounds were toxic to primary cells, we obtained peripheral human 
B-cells, treated them with DMSO or the compounds, and determined viability by performing 
trypan blue exclusion assays. The results showed that the compounds had a minimal effect on 
the viability of primary B-cells (Figure 3.10A). Interestingly, the cells were treated at 2.5 µM, 
which is higher than the EC50 calculated on most cells. Furthermore, to determine whether the 
inhibitors reduced the activation of the pathway in primary B-cells, cells were treated for 24 h 
with miransertib, sirolimus, or the combination, and immunoblots were performed for pFOXO1. 
The results showed that while sirolimus has no effect on pFOXO1, miransertib alone or in 
combination with sirolimus has only a slight reduction in the phosphorylation of the protein 
(Figure 3.10B).  
Finally, we wanted to determine whether the combination of miransertib and sirolimus 
had a more substantial cytotoxic effect on primary B-cells. To do that, we treated primary B-
cells with the Akt inhibitors and sirolimus alone or in combination at a concentration where the 
combination was enough to reduce viability to about 50% in NHL cells (Figure 3.4A, Figure 
3.6A, Figure 3.8A). The results demonstrated that in contrast to NHL cells, the combination did 
not strongly reduce the viability of normal cells (Figure 3.10C). Interestingly, in terms of 
FL-18), sirolimus (10 nM) or the combination of the Akt and mTORC1 inhibitor at the 
indicated concentrations. The caspase-3 assays were performed as in panel A. The mean ± STD 
of 3 experiments is depicted in the bar graph. *p<0.05 determined by Welch's t-test. (E) FL-18, 
BJAB, and BCBL-1 cells were treated for 48 h with DMSO, miransertib (5 µM for BJAB and 
BCBL-1, and 10 µM for FL-18), sirolimus (5 nM), or the combination of both inhibitors. 
Immunoblots were performed to detect the levels of PARP and the loading control β-actin. The 
red arrow points to cleaved PARP. (F) FL-18, BJAB, and BCBL-1 cells were treated as in 
panel E and immunoblots were performed for cleaved-caspase 7 and the loading control β-
actin. 
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viability, the combination of miransertib and sirolimus had a similar effect to those observed 
with the dual PI3K/mTOR inhibitor, dactolisib. Altogether, these results suggest that the 
Figure 3.10 Miransertib and MK-4440 are not toxic to human primary B cells. 
(A) Human primary B-cells were treated with DMSO, miransertib (2.5 µM), or MK-4440 (2.5 
µM), and the number of live cells was manually counted by excluding dead cells stained with 
trypan blue. Every dot represents one of six biological replicates. (B) Primary B-cells were 
treated for 24 h with DMSO, miransertib (2.5 µM), sirolimus (5 nM), or the combination of 
both inhibitors. Immunoblots were performed to detect pFOXO1, FOXO1, and the loading 
control β-actin. (C) Human primary B-cells were treated with DMSO, miransertib (0.31 µM), 
MK-4440 (0.31 µM) sirolimus (0.13 nM), miransertib (0.31 µM) + sirolimus (0.13 nM), MK-
4440 (0.31 µM) + sirolimus (0.13 nM), or dactolisib (6.5 nM), and the number of live cells 
were manually counted by excluding dead cells stained with trypan blue. 
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compounds might have a more potent effect on NHL cells, which might be due to their 
addiction to the PI3K/Akt/mTOR pathway. 
 
DISCUSSION 
The numerous therapeutical approaches used to treat NHL demonstrate the 
heterogeneity of these malignancies and the lack of a broadly efficacious therapy. The 
continued discovery of molecular targets and novel treatments is vital to improving overall 
survival for this disease cluster. One signaling pathway that has attracted attention in NHL is the 
PI3K/Akt/mTOR network (Figure 3.11) (298). Supraphysiological activation of this pathway 
can result from activating mutations in the PI3K isoforms and Akt, the loss of the negative 
regulator PTEN and the introduction of viral oncogenes. In addition to being vital to the 
survival of cancer cells, this signaling pathway's hyperactivation is believed to be an important 
player in drug resistance (314). For instance, the resistance of activated B-cell DLBCL cell lines 
to the Bruton's tyrosine kinase inhibitor, ibrutinib, is mediated through the overactivation of the 
PI3K/Akt/mTOR (315, 316). Conversely, PI3K inhibitors synergized with chemotherapy agents 
against ibrutinib-resistant DLBCL cells. These examples highlight the vital role that this 
signaling pathway might play as a therapeutic target against NHL.  
In recent years, three PI3K inhibitors (duvelisib, copanlisib, and idelalisib) have 
received approval from the United States Food and Drug Administration (FDA) to treat 
refractory FL and are currently in clinical trials for other NHL subtypes (300-302). An 
additional PI3Kα inhibitor, alpelisib, in combination with fulvestrant, was approved in 2019 to 
treat certain breast cancers (317). mTOR belongs to the family of phosphatidylinositol 3-kinase-
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related protein kinases due to its similarity with PI3K. The pharmacological inhibition of mTOR 
Figure 3.11 Summary. 
Simplified model of the PI3K/Akt/mTOR pathway, including the compounds and their 
respective target. The in vitro studies demonstrated that the combination of miransertib or MK-
4440 and sirolimus was synergistic against a variety of NHL cell lines. In the in vivo studies, 
the follicular lymphoma model was highly sensitive to miransertib treatment alone. The diffuse 
large B-cell lymphoma models were slightly sensitive to miransertib, but the addition of 
sirolimus strongly repressed tumor growth. For the highly aggressive primary effusion 
lymphoma model, only mice treated with the combination of Akt and mTOR inhibitors 
suppressed tumor growth. Created with Biorender. 
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through rapamycin and its derivatives (rapalogs) has been approved for various treatments, 
including cancers, and studied in the context of lymphomas. Feng et al. discussed in detail the 
development of these compounds against hematological malignancies (318). To mention a few, 
several phase I-II trials have been conducted to test the efficacy of these compounds (e.g., 
everolimus and temsirolimus) and have shown some efficacy as monotherapy or in combination 
with other standard chemotherapy regimens such as R-CHOP or lenalidomide (319-322). 
Furthermore, a recent study demonstrated the efficacy of the combination of the HDAC 
inhibitor, vorinostat, in combination with sirolimus or everolimus in heavily treated 
relapsed/refractory lymphoma patients (323). Although mTOR inhibition has shown some 
clinical value, the development of these compounds for such indications has slowed down, as 
demonstrated by the lack of active phase III trials (318).  
Akt inhibitors have lagged behind in discovery and clinical development. An extensive 
literature review on the development of Akt inhibitors was recently published by Song et al. 
(324). Some of the most promising candidates include the ATP-competitive Akt inhibitors 
capivasertib (AZD5363) and ipatasertib (GDC-0068) and the allosteric inhibitor MK-2206. All 
three compounds have progressed through clinical trials with mixed results (325-327). Several 
phase III trials are ongoing using capivasertib combined with compounds such as paclitaxel, 
abiraterone, palbociclib, or fulvestrant for the treatment of a variety of conditions, including 
breast cancers (NCT03997123; NCT04862663; NCT04305496) and prostate cancers 
(NCT04493853). Notably, some clinical data has demonstrated that patients with aberrant 
PI3K/Akt/mTOR tend to show the best response highlighting the pathway as a possible 
indicator for therapy selection (325). On the other hand, although Roche's ipatasertib in 
combination with paclitaxel had promising phase I-II data as first-line treatment for metastatic 
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triple-negative breast cancer, in phase III trials, the combination failed to reach the primary 
endpoint (328, 329). Similarly, MK-2206 has demonstrated a manageable safety profile but has, 
for the most part, failed to show clinical efficacy, including in refractory lymphoma patients 
(330). The encouraging results seen with capivasertib demonstrate the likely clinical benefit in 
targeting Akt. Therefore, a significant research effort should be centered on characterizing novel 
compounds.  
Miransertib is one of the most recent Akt inhibitors to enter clinical trials. Given the 
importance of Akt, commonly known as the "cell survival kinase," we explored miransertib for 
its therapeutic benefits against NHL. Some pre-clinical and early clinical studies have 
demonstrated the efficacy of the orally bioavailable pan-Akt inhibitor miransertib against 
certain cancers (304, 331, 332). Preliminary results of a phase I trial in heavily pretreated NHL 
and chronic lymphocytic leukemia patients showed that 3/11 patients had a partial response to 
miransertib (332). Moreover, miransertib is currently undergoing a phase II trial 
(NCT04316546) to treat a rare but progressive overgrowth syndrome (Proteus syndrome) that 
arises from the E17K mutation in Akt with case reports showing single-agent activity (333-
335). Notably, no toxicities were reported in these case studies, which included pediatric cases. 
Thus, we wanted to test whether the Akt inhibitors miransertib and MK-4440 are effective 
against NHL spanning indolent to aggressive forms. We found that both Akt inhibitors reduced 
the activation of the PI3K/Akt/mTOR signaling pathway, decreased cell proliferation, and had 
efficacy in xenograft models. The effect was subtype-dependent. Some cell lines were more 
drug-resistant than others. Cell lines representing mantle cell lymphoma and Burkitt's 
lymphoma (BL) were amongst the most resistant (Appendix 13, Appendix 14, and Table 3.1). 
Our results obtained with BL are consistent with a recent report showing that BL cells grow 
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despite high PTEN levels and are not sensitive to Akt inhibition (306). Most other subtypes, 
specifically FL, DLBCL, and PEL, were sensitive to Akt inhibition.  
Interestingly, although treatment with miransertib or MK-4440 alone strongly inhibited 
Akt, the pathway remained active as downstream targets were slightly phosphorylated primarily 
in DLBCL and PEL cells. This leftover activation might be responsible for the higher resistance 
detected in these cells as compared to FL. Previous studies in DLBCL demonstrated that Akt-
independent activation of S6K through upregulation of Pim2 or the B-cell receptor is a 
significant driver of resistance to Akt inhibition (336). Furthermore, KSHV viral proteins are 
believed to be important drivers of tumorigenesis in PEL cells, and several of these proteins 
have been found to activate the PI3K/Akt/mTOR signaling pathway (39). One such protein is 
the product of ORF36, viral protein kinase, which resembles S6K and phosphorylates S6 (239). 
Similarly, upregulation of IL-6 and JAK/STAT signaling was reported as a resistance 
mechanism against PI3K inhibitors in lymphoma (337). Notably, KSHV encodes for a viral 
homolog to IL-6, which constitutively activates JAK/STAT signaling (205). Therefore, there are 
multiple avenues for which extrinsic factors such as viral proteins and intrinsic factors such as 
mutations or overactivation of parallel pathways might drive resistance to Akt inhibition.  
The dual PI3K and mTOR inhibitor compound dactolisib (NVP-BEZ235) is broadly 
effective against NHL, inducing cell death and strongly repressing the PI3K/Akt/mTOR 
pathway (311, 338); however, the clinical development of dactolisib was terminated due to 
toxicity (339-341). The EC50 of dactolisib against NHL was <10 nM, which is significantly 
lower than what we observed with miransertib and MK-4440. Furthermore, dactolisib strongly 
repressed tumor growth at a concentration of ~40 mg/kg, whereas for miransertib, we used 100 
mg/kg (311, 338). The experience with dactolisib provides proof of principle that combined 
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inhibition of multiple targets in this pathway is broadly efficacious. Our results support this 
paradigm. Neither miransertib nor MK-4440 alone completely inactivated the pathway as 
determined by phosphorylation of S6, but the combined inhibition of Akt and mTOR 
synergistically reduced cell growth. The advantage of this approach compared to using one 
compound that targeted two kinases, as in the case of dual inhibitors, is that the dose of each 
inhibitor, miransertib, or sirolimus, can be adjusted individually to provide maximum benefit 
and minimum cytotoxicity. 
The combined inhibition of mTORC1 and Akt prevented the mTORC2-mediated 
phosphorylation of Akt at residue 473. This phosphorylation is usually increased upon 
inhibition of mTORC1 by sirolimus and is predicted to contribute to drug resistance (23, 310). 
The newer generation of mTORC1 and mTORC2 inhibitors might provide an even more robust 
effect. 
Follicular lymphoma stood out in our survey because this tumor type seemed exquisitely 
sensitive to even single agents. Here the administration of miransertib or sirolimus significantly 
reduced the tumor growth in the FL-18 model. The combination of both inhibitors did not 
prevent tumor growth beyond the effect seen in mice treated with monotherapy, even though the 
tumors from the dually-treated group expressed the lowest amount of pS6. Unfortunately, in 
vitro models for studying FL are limited as patient-derived cell lines resemble transformed FL 
(342). The lack of resources in this and other FL studies provides a challenge for collecting pre-
clinical data with unadulterated FL.  
In the case of DLBCL, both BJAB and Karpas-422 xenografts responded the best when 
treated with the combination of miransertib and sirolimus. Both immunohistochemistry and 
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immunoblots demonstrated a reduction in the phosphorylation of S6, suggesting that the 
compounds reached the tumors in vivo. Similarly, a substantial reduction in tumor growth in the 
PEL xenograft was only attained in the arm treated with the combination. Interestingly, 
although the combination of miransertib and sirolimus reduced pS6 in PEL tumors, it had 
minimal effect on pAkt. Since the BCBL-1 xenografts have both solid and liquid components, it 
is possible that our compounds did not completely reach the solid tumors even though they 
strongly repressed the dissemination of ascites. These observations illustrate the difficulties of 
treating lymphomas composed of effusions such as PEL.   
Several Akt targets are directly involved in the inhibition of apoptosis (343). These 
targets include the FOXO family of proteins (33). Our results demonstrated that Akt inhibition 
increased the levels of FOXO1 protein. Thus, we reasoned that miransertib and MK-4440 
should trigger the induction of apoptosis, which might be responsible for decreasing cell 
viability. To analyze the apoptotic state in treated cells, we measured the activity of caspase-3 
and the presence of cleaved PARP and caspases-3 and 7. These studies demonstrated that 
inhibition of Akt induced the activation of apoptotic signaling and it was increased when 
combined with sirolimus. Altogether, inhibition of Akt in several NHL cell lines induces 
apoptosis and might be responsible for the reduction in cell growth.  
In conclusion, this report demonstrates the feasibility and need for targeting Akt and 
mTORC1 as a treatment for NHL. To our knowledge, this report is the first one that uses a 
variety of in vitro and in vivo models to demonstrate the approach against hematological 
malignancies. Although this study examines miransertib and sirolimus as an all-oral regimen 
that might achieve this goal, we believe that this strategy should continue to be explored with 
newer and more specific inhibitors.   
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS
 
SUMMARY 
My dissertation work performed under the guidance of Dr. Blossom Damania expanded 
our knowledge on the role of signaling pathways in mediating the tumorigenesis of Kaposi’s 
sarcoma-associated herpesvirus (KSHV). The ability of the virus to hijack and modulate cellular 
signaling pathways is a vital step that facilitates viral replication and survival of the infected 
cells. Importantly, when cells lose their self-control, and pro-tumorigenic signaling pathways 
become constitutively active by either genetic lesions or exogenous factors like viral proteins, 
cancers might develop. Targeting these signaling pathways directly (e.g., kinases) or their 
effectors (e.g., cytokines) is a therapeutic option that has been effective for many human cancers 
and might be a feasible approach against viral cancers. In this dissertation, I aimed to address 
this question by first uncovering novel proteins involved in KSHV-induced pro-tumorigenesis 
and then targeting a pathway known to be necessary for the survival of KSHV-associated 
lymphoma. 
In Chapter 1, which included sections previously published in Frontiers in 
Microbiology, I outlined some of the current knowledge about the role of KSHV in modulating 
signaling pathways and how this process can lead to tumorigenesis with an emphasis on 
angiogenesis (255). As a herpesvirus, KSHV encodes a large dsDNA genome that expresses 
many genes and non-coding RNAs. The expression of these factors depends on the virus life 
cycle, with some being expressed only during lytic replication. Regardless of the timing of 
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expression, many of these factors induce signaling pathways such as the JAK/STAT and 
PI3K/Akt/mTOR. Consequently, similar to non-viral cancers, the chronic deregulation of these 
signaling pathways can facilitate tumor growth by promoting processes such as cell growth 
while preventing cellular events such as apoptosis. 
Furthermore, both pathways are known to create a pro-tumorigenic microenvironment 
by recruiting pro-inflammatory cells and the induction of angiogenesis. To identify novel 
effectors of these signaling pathways, the laboratory previously performed a transcriptomic 
analysis from endothelial cells expressing the KSHV protein, vIL-6. The results from this 
experiment were the basis for the studies presented in Chapter 2 (131). 
 
KAPOSI’S SARCOMA-ASSOCIATED HERPESVIRUS VIRAL INTERLEUKIN 6 
SIGNALING UPREGULATES INTEGRIN BETA 3 LEVELS AND IS DEPENDENT ON 
STAT3 
In the second chapter of my dissertation published in the Journal of Virology, we found 
the mechanism by which the oncogenic viral protein, vIL-6, induces the expression of ITGB3, 
which we identified to be important for the ability of vIL-6 to induce angiogenesis in vitro and 
might represent a therapeutic target (344). We found that, in endothelial cells, vIL-6 promotes 
the activation of the ITGB3 promoter resulting in an increase in the expression of ITGB3 at the 
mRNA and protein levels (Figure 2.1). Following the increase in expression, we detected higher 
levels of the heterodimer integrin αVβ3 localizing to the plasma membrane. Furthermore, we 
found that secreted vIL-6 from either endothelial cells, B-cells, or epithelial cells can induce the 
expression of ITGB3 in a paracrine manner (Figure 2.2 and Figure 2.3). 
To gain insight into the mechanisms involved in the induction of ITGB3, we used a 
combination of inhibitors and siRNAs to test the role of the JAK/STAT signaling pathway. 
First, we found that, in endothelial cells, vIL-6 co-immunoprecipitates with gp130 and that 
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silencing this receptor reduces vIL-6-induced ITGB3 (Figure 2.4). Furthermore, inhibition or 
knockdown of STAT3 reduced the induction of ITGB3, confirming that the pathway plays a 
vital role in this process. Notably, we found that contrary to vIL-6, human IL-6 cannot induce 
ITGB3 in endothelial cells unless those cells are exogenously supplemented with soluble IL-6 
Rα (sIL-6Rα), owing to the fact that human IL-6 does not interact directly with gp130 and IL-
6Rα expression is limited in this cell type (Figure 2.5). 
We then asked about the functionality of vIL-6-expressing cells having higher levels of 
ITGB3. Current knowledge on integrins indicates that in endothelial cells, integrin αVβ3 plays 
an essential role in mediating angiogenesis, and vIL-6 is a highly angiogenic protein (87, 255, 
345-347). Therefore, we asked whether ITGB3 is important for vIL-6-induced angiogenesis. 
We found that knockdown of ITGB3 reduced the ability of vIL-6-expressing cells to adhere to 
ECM components and form tubules, which served as an in vitro model to test for angiogenesis 
(Figure 2.6 and Figure 2.7). Losing the capacity to adhere and form tubules can jeopardize the 
angiogenic potential of these cells (348). To conclude, the studies performed for this chapter 
highlighted ITGB3 as a potential target for KSHV-associated malignancies. However, many 
questions remained unanswered, and addressing them will help better understand the role of 
ITGB3 in viral-induced oncogenesis. Some of these questions are presented below.  
Our data demonstrated a role for ITGB3 in mediating vIL-6-induced angiogenesis in 
vitro; however, we do not know the mechanisms by which this integrin facilitates this process. 
Previous studies have demonstrated that integrin αVβ3 antagonists induce apoptosis of 
endothelial cells and increase the activity of proteins such as p53 and p21 while decreasing 
expression of the anti-apoptotic proteins BCL2-associated X protein (345). In our studies, we 
found that transient knockdown of ITGB3 did not reduce the viability of the cells (Appendix 2).  
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Furthermore, activation of MAPK, FAK, and Src has been attributed to integrins 
mediating cell migration and proliferation, which are essential for the formation of new blood 
vessels (345). Although integrins lack enzymatic activity, they serve as scaffold proteins 
recruiting protein complexes to mediate signal transduction pathways. Notably, the integrin 
αVβ3 plays a critical role in mediating FGF- and TNF-α-induced angiogenesis (243). As 
mentioned in Chapter 1, the expression of these two proteins is elevated in KSHV malignancies. 
Integrin αVβ3 has been shown to interact with several RTKs known to have roles in 
mediating angiogenesis (Figure 4.1). Among these, VEGFR-2 might be the most thoroughly 
studied due to its ligand, VEGFA. The crosstalk between VEGFR-2 and integrin αVβ3 
facilitates the phosphorylation of both proteins' cytoplasmic domains, which allows for full 
activation and the recruitment of additional proteins (347). One kinase involved in this process 
is Src. Several studies have identified Src as the kinase driving phosphorylation of two residues 
(Y773, Y785) in the cytoplasmic tail of ITGB3 (349). Once phosphorylated, protein complexes 
containing FAK, talin, paxillin, and others, are recruited, facilitating the activation of signaling 
pathways, including PI3K/Akt/mTOR and MAPK/ERK. Interestingly, a recent report found that 
resistance to FAK inhibitors in pancreatic ductal adenocarcinoma is mediated through an 
increase in STAT3 activity, hinting that JAK/STAT signaling might also have a role in integrin 
signaling (350). Activation of these pathways is hypothesized to be essential for the induction of 
angiogenesis. Since KSHV proteins are known to deregulate these pathways, it would be 
interesting to determine if ITGB3 plays a role in mediating viral-induced signaling. 
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One outstanding question that needs to be answered is how does ITGB3 mediates vIL-6-
induced angiogenesis (Figure 4.1A and B). ITGB3 can deploy multiple mechanisms to 
Figure 4.1 Does ITGB3 play a role in activating signaling pathways promoting 
angiogenesis in vIL-6-expressing cells?  
(A-B) Are ITGB3’s roles in angiogenesis mediated through the adaptor proteins recruited to its 
cytoplasmic tails (A) or through the interactions with RTK (B)? Is the integrin αVβ3 required 
for vIL-6- or KSHV-induced tumors in vivo? (C) Would inhibition of integrins perturb vIL-6-
induced tumors? Created with Biorender. 
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accomplish this process (345). One possible mechanism is that the increase in the levels of 
integrin αVβ3 allows for the recruitment of additional non-receptor tyrosine kinases such as 
FAK, and p21-activated kinase 1 (PAK1), resulting in the activation of signaling pathways 
(Figure 4.1A) (351, 352). Notably, both kinases have been identified as mediators of signaling 
induced by the KSHV proteins K1 and vGPCR (148, 165, 353). To elucidate how ITGB3 
mediates vIL-6-induced angiogenesis, I would evaluate the levels of phosphorylated-FAK and -
PAK1 in vIL-6-expressing cells and EV controls. If the levels of activated FAK and PAK1 are 
unaffected in the vIL-6-expressing cells, ITGB3 might be using an alternative mechanism such 
as the involvement of RTKs (Figure 4.1B). To test this hypothesis, I would evaluate the levels 
of phosphorylated receptors such as VEGFR-2, PDGFRβ, cMet, and EGFR in vIL-6-expressing 
cells and EV cells. If the results show no differences, it would be interesting to create vIL-6-
expressing cells lacking ITGB3 and perform a transcriptomic and phosphoproteomic analysis to 
determine the genes and proteins deregulated.  
The overarching goal of this project was to identify potential therapeutic targets, and 
ITGB3 positions itself as an interesting candidate. Therefore, two questions that I would like to 
address are whether ITGB3 is necessary for the growth of vIL-6-induced tumors and whether 
treatment with ITGB3 antagonists reduces tumor growth (Figure 4.1C).  
In the early 2000s, inhibitors of integrins gained much attention due to their anti-
angiogenic potential and even reached phase III trials (354-356). These inhibitors included 
RGD-containing peptides and humanized antibodies. Unfortunately, for the most part, these 
therapeutic agents have failed to demonstrate clinical efficacy against several cancers, and their 
development has slowed down. Development of cilengitide was discontinued as it did not 
improve progression-free or overall survival during phase III trials in glioblastoma patients 
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(356). Cilengitide is a cyclic RGD-containing peptide that binds to αVβ3- and αVβ5-expressing 
cells. The clinical failures of this compound, despite encouraging preclinical studies, can be 
attributed to other factors beyond its target. For example, cilengitide has suboptimal 
pharmacokinetics exemplified by its very short half-life of just a few hours and requires 
intravenous administration. However, a constant infusion of the inhibitor or different 
formulations were not evaluated. Additionally, other studies showed that treatment of tumors 
with low concentrations of cilengitide can promote angiogenesis, counteracting one of the major 
purposes of developing this type of compound. Furthermore, the selection of subjects for the 
glioblastoma phase III trial required them to have a methylated O-6-methylguanine-DNA 
methyltransferase promoter even though minimal data demonstrate an association of this 
promoter and αVβ3 activation. Thus, some of these factors might have contributed to the lack of 
efficacy demonstrated by cilengitide against several cancers.  
Molecules targeting pan-αV or selectively αVβ3 have been developed and have entered 
clinical assessment. For example, etaracizumab (MEDI-522) is specific to αVβ3 and showed 
good tolerability alone or combined with chemotherapy but failed to show efficacy or anti-
angiogenic activity (357-359). Similarly, the anti-αV antibody intetumumab (CNTO95) showed 
a good safety profile but did not show clinical benefit in phase II trials against melanoma (360, 
361). Moreover, abituzumab (EMD 525797/DI17E6) is also an anti-αV antibody that, although 
the primary endpoint of progression-free survival was not achieved in a phase II trial, showed 
activity against prostate cancer bone metastasis. However, its development has also been 
paused. 
Although the clinical development of compounds and molecules targeting integrins have 
faced roadblocks, these trials have demonstrated that targeting integrins is a safe and tolerable 
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approach, and it is possible that newer generations of inhibitors might finally prove to be 
effective. Importantly, the screening for integrin inhibitors has been performed based on the 
therapeutic candidate's capacity to prevent cell adhesion or migration. As mentioned above, 
although these two processes are essential for metastasis and angiogenesis, integrins play 
additional roles that might mediate tumorigenesis. Moreover, the mechanisms of action by the 
investigational drugs or biologics tested so far have usually relied on the ability of the inhibitor 
to compete with integrin ligands by binding to the ligand-binding pocket or by sterically 
preventing ligand binding. However, preventing the binding of ligands might not lead to 
inactivation; in contrast, it might cause a “superactive” conformation sustaining the activation of 
downstream signaling through its interaction with kinases or adaptor proteins, which might 
result in the promotion of tumorigenesis. In fact, treatment with low concentrations of 
cilengitide can increase the vasculature of tumors and increase the permeability of endothelial 
cells by disrupting vascular-endothelial cadherin (362, 363). Interestingly, this potential 
function has been hypothesized to be useful in delivering chemotherapy agents directly to the 
tumors and might provide an avenue for repurposing these inhibitors (355, 362, 364).  
To assess whether ITGB3 is necessary for the growth of vIL-6-induced tumors, I will 
perform xenograft studies with vIL-6-expressing cells deficient in ITGB3. Additionally, treating 
mice with integrin antagonists such as cilengitide would allow me to test whether ITGB3 can be 
considered a viable therapeutical target. Furthermore, if the in vitro studies delineated above 
identifies a specific RTK (e.g., VEGFR-2) or a non-receptor tyrosine kinase (e.g., FAK) as a 
player in vIL-6-induced and ITGB3-mediated angiogenesis, it would be interesting to test the 
feasibility of targeting both the kinase and integrin. Ideally, this approach can be exploited with 
the use of bispecific antibodies, which can be engineered to target two individual 
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transmembrane proteins. In fact, single molecules targeting αVβ3 and VEGFR-2 or Tie-2 have 
been reported and shown to have anti-angiogenic activity (365, 366).  
Importantly, if inhibition of integrin alone or in combination with tyrosine inhibitors 
results in a reduction in tumor growth, it would be interesting to determine if this effect is due to 
a decrease in angiogenic activity. This can be addressed by performing assays such as Evans 
Blue (Miles vascular permeability) and by detecting endothelial cell makers such as CD31 and 
endomucin on the tumors and surrounding tissue (367). Lastly, if the therapeutic approach 
effectively reduces the tumor growth induced by vIL-6, it would be interesting to test the 
method with a KSHV-infected cell line such as the telomerase-immortalized human umbilical 
vein endothelial cells (TIVE) (368, 369). TIVE cells contain the KSHV genome and induce KS-
like tumors in mice. Together, the future directions proposed here would allow me to use in 
vitro and in vivo models to characterize the role that ITGB3 plays in KSHV-induced 
tumorigenesis. 
In sum, we identified the pro-angiogenic protein ITGB3 as a factor induced by the 
KSHV protein vIL-6, which might have a potential role in mediating tumor growth and might 
represent a therapeutic target.  
 
COMBINED INHIBITION OF AKT AND MTOR IS EFFECTIVE AGAINST NON-
HODGKIN LYMPHOMAS 
In Chapter 3, which was published in the journal Frontiers in Oncology, we evaluated 
the efficiency of novel Akt inhibitors alone or in combination with an mTORC1 inhibitor for the 
treatment of non-Hodgkin lymphomas (NHL), including PEL (370). As discussed above, the 
PI3K/Akt/mTOR pathway is usually deregulated in various cancers, including NHL, and several 
KSHV factors have been identified to promote the activation of the pathway and essential for 
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the cell’s survival (39). Thus, we reasoned that inhibition of the signaling network with novel 
Akt inhibitors should reduce cell viability. We used a combination of in vitro and in vivo tools 
with a large panel of cell lines representing five NHL subtypes to address this hypothesis (Table 
3.1). We found that the Akt inhibitors miransertib and MK-4440 reduced the viability of cells in 
culture in a subtype-dependent manner (Figure 3.3, Figure 3.5, and Figure 3.7). This reduction 
in viability was consistent with a decrease in phosphorylated Akt and its downstream targets. 
Interestingly, we found that even though Akt was strongly repressed, the pathway 
remained active, which prompted us to test a strategy of inhibiting mTORC1 in addition to Akt. 
This dual inhibition strongly and synergistically repressed cell growth and inactivated the 
pathway (Figure 3.4, Figure 3.6, and Figure 3.8). Importantly, inhibition of the pathway 
triggered the induction of pro-apoptotic proteins, which might be the mechanism accounting for 
the reduction in cell proliferation (Figure 3.9). These results encouraged us to test our strategy 
in vivo.  
Using a combination of xenograft models, we found that our combinatorial strategy 
effectively prevented tumor growth in three NHL subtypes. In our survey, FL stood out as 
highly sensitive to treatment with miransertib alone, whereas DLBCL and PEL benefited the 
most from the dual inhibition (Figure 3.4, Figure 3.6, and Figure 3.8). The analysis of the 
tumors demonstrated that the pathway was inactivated, confirming that the drugs were reaching 
the tumors. Finally, we found that primary B-cells were not very sensitive to the inhibitors, 
contrary to the effect seen in NHL cells (Figure 3.10). In summary, in this study, we 
demonstrated the potential benefit of inhibiting both Akt and mTORC1 with a combination of a 
novel (miransertib and MK-4440) and proven (sirolimus) compounds as an effective strategy 
against the KSHV-associated lymphoma, PEL, and applicable to other NHL. However, this 
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work raised several questions, and addressing them would provide a better understanding of the 
biology of lymphomas.  
For the FL studies (Figure 3.3 and Figure 3.4), we used two cell lines isolated from FL 
patients. However, these cell lines typify transformed FL and are not the ideal representatives of 
the most common indolent subtype; thus, it would be interesting to perform in vitro experiments 
with primary FL cells and in vivo studies with patient-derived xenografts. Furthermore, tumors 
evolve and create resistance to chemotherapeutic agents, leading to therapeutical failures (371). 
Resistance can arise due to multiple mechanisms, including mutations in the targeted protein, 
resulting in the compounds losing their affinity, the upregulation of isoforms of the targeted 
protein, or the activation of parallel signaling pathways allowing them to have compensatory 
roles. Understanding the mechanisms underlying drug resistance is essential for predicting the 
efficacy of treatments and possibly designing combinatorial therapies (371, 372). 
Interestingly, Akt3 was found to be upregulated in breast cancer cells that were made 
resistant to the Akt inhibitor MK-2206 (373). Thus, it would be worthwhile to create NHL cells 
resistant to the Akt inhibitors and perform transcriptomic and phosphoproteomic analysis to 
determine whether chronic inhibition of Akt with miransertib or MK-4440 drives the 
upregulation of Akt isoforms or parallel pathways such as MAPK/ERK (Figure 4.2A). If 
upregulated pathways are uncovered in the resistance cells, it would be of significant interest to 
test whether the inhibition of these signaling networks overcomes the increase in survival 
caused by the resistance to Akt inhibition. 
An additional unanswered question is whether inhibition of Akt in these lymphoma cells 
reduces their pro-angiogenic roles (Figure 4.2C). Although lymphoma and liquid tumors are not 
usually studied in the context of angiogenesis, recent studies have demonstrated that 
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angiogenesis might be essential for maintaining the tumor microenvironment and avoiding 
immune surveillance (374). For example, expression of VEGFA and its receptors have been 
found in DLBCL tumors, and the more aggressive cases tend to have higher levels of both 
proteins (375). Similarly, PEL cells secrete pro-angiogenic factors such as VEGFA and FGF, 
facilitating the formation of tubules by endothelial cells (107, 376). In DLBCL, expression of 
Figure 4.2 Outstanding questions regarding the combined inhibition of Akt/mTORC1 in 
NHL.  
(A) Would chronic inhibition of Akt activate parallel signaling pathways? (B) Would newer 
inhibitors of the pathway have improved efficacy and better safety profiles? (C) Would 
inhibition of Akt/mTORC1 reduce the expression and secretion of pro-angiogenic factors? (D) 
Does inhibition of Akt affect KSHV reactivation of PEL cells? Created with Biorender. 
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VEGFR-2 has been associated with poor prognosis in patients treated with R-CHOP (377). It 
has been established that inhibition of the PI3K/Akt/mTOR pathway reduces the expression and 
secretion of growth factors, and it would be of interest to determine whether our combinatorial 
approach has anti-angiogenic effects. 
Lastly, the PI3K/Akt/mTOR pathway has been shown to have some involvement in 
KSHV reactivation. Therefore, I wonder whether miransertib- and MK-4440-mediated 
inhibition of Akt affects viral reactivation in PEL cells (Figure 4.2D). On the one hand, it was 
shown that inhibition of the pathway reduced HSV-1-induced reactivation of BCBL-1 cells 
(378). On the other hand, Peng et al. showed that the pathway suppresses reactivation, and its 
inhibition increases viral replication (379). However, our group found that K1 is necessary for 
reactivation, hinting at the possibility that the PI3K/Akt/mTOR pathway is involved since a K1-
deficient virus did not induce phosphorylation of Akt (380). Elucidating whether our Akt 
inhibitors alone or in combination with sirolimus induce viral reactivation is important as it 
might open avenues to test “shock and kill” strategies. 
 In sum, the work performed in Chapter 3 delineated a therapeutical approach to treat 
NHL spanning from indolent to aggressive by targeting both Akt and mTORC1 and provided 
the rationale to continue exploring this approach with newer and more specific inhibitors 
(Figure 4.2B).  
 
CONCLUSIONS 
To conclude, with this dissertation, I undertook two different routes to contribute to both 
fields of virology and oncology by providing new knowledge on the biology of KSHV and 
testing a novel strategy for treating KSHV-associated malignancies with implications beyond 
viral cancers. Although cases of KSHV-associated diseases decreased with the advent of cART, 
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a recent report indicates that these cancers are now being seen at an increasing rate in the 
context of cART due to the fact that HIV-positive individuals are aging and living longer (59). 
Additionally, these malignancies are still a threat in some areas of the world due to endemic 
KSHV infection and to our aging population. Understanding the mechanisms by which the virus 
exploits its host is essential for developing therapeutics, and this work sought to shed some light 
on approaches to improve patients’ lives. The work must continue to address many outstanding 
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Appendix 2 Transient knockdown of ITGB3 is not toxic to HUVEC. 
Cells were transfected with siNTC or siITGB3 and viability was determined with trypan blue at 
24 h and 48 h post-transfection. 
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APPENDIX 3 
   
Immunohistochemistry against pS6 (S235/6) performed to BJAB tumor sections. Sections were 
developed with DAB (3,3′-diaminobenzidine) and counterstained with hematoxylin. (Scale 
bars, 100 μm). yellow = weak staining, orange = medium staining, red = strong staining. 




Appendix 4 Washout of Akt inhibitors. 
FL-18, BJAB, and Karpas-422 cells were treated for 2 h with 1 µM of miransertib or MK-
4440. After the 2-h period, media containing the inhibitors was removed, cells were washed 
and incubated in fresh medium without compounds and cells were then collected at 0, 2, 4, 6, 
and 24 h after the washout. 
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APPENDIX 5  
  
Appendix 5 Combination of miransertib and sirolimus in FL-18 and BJAB cells. 





Appendix 6 Animal weights throughout xenograft experiments. 
NSG mice were injected with FL-18 and BJAB cells and treated with the indicated compounds. 




Appendix 7 Additional images of immunohistochemistry performed on FL-18 tumors. 
Immunohistochemistry against pS6 (S235/6) performed to tumor sections. Sections were 
developed with DAB (3,3′-diaminobenzidine) and counterstained with hematoxylin. (Scale 




Appendix 8 Additional images of immunohistochemistry performed on BJAB tumors. 
Immunohistochemistry against pS6 (S235/6) performed to tumor sections. Sections were 
developed with DAB (3,3′-diaminobenzidine) and counterstained with hematoxylin. (Scale 




Appendix 9 Additional images of immunohistochemistry performed on Karpas-422 
tumors. 
Immunohistochemistry against pS6 (S235/6) performed to tumor sections. Sections were 
developed with DAB (3,3′-diaminobenzidine) and counterstained with hematoxylin. (Scale 




Appendix 10 The Akt inhibitors miransertib and MK-440 are toxic to PEL cells. 
BC-1, BCBL-1, and VG-1 cells were treated for 72 h with increasing concentration of the Akt 




Appendix 11 Additional images of immunohistochemistry performed on BCBL-1 tumors. 
Immunohistochemistry against pS6 (S235/6) performed to tumor sections. Sections were 
developed with DAB (3,3′-diaminobenzidine) and counterstained with hematoxylin. (Scale 




Appendix 12 Treatment with miransertib or MK-4440 induces the cleavage of caspase-3. 
BC-1, BCBL-1, BJAB, and JSC-1 cells were treated for up to 72 h and immunoblots were 




Appendix 13 Effect of Akt inhibitors on mantle cell lymphoma cells. 
(A) The mantle cell lymphoma cell lines Granta-519 (i), JeKo-1 (ii), JVM-2 (iii), and Rec-1 
(iv) were treated for 72 h and viability was determined by CellTiter-Glo. (B) JVM-2 and Rec-1 





Appendix 14 Effect of Akt inhibitors on Burkitt’s lymphoma cells. 
BL-41 (i), Daudi (ii), Raji (iii), and Ramos (iv) cells were treated for 72 h and viability was 
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